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Abstract
Proteins rarely act alone. They often undertake biological functions as
components of larger molecular machines characterized by intricate physic-
ochemical dynamic connections. Current research efforts increasingly point
to genome-wide screenings for protein complexes. These data have to be
integrated with structural information in order to gain insights into func-
tional aspects. In this context, computational studies play a crucial role,
being able to complement experimental data. In this thesis, I have used
computational methods to unravel key aspects of several pharmacologically
relevant protein complexes, using increasingly sophisticated computational
tools.
By using molecular modeling and classical molecular dynamics, I have pre-
dicted the atomic details of the protein complex formed by Granzyme B
and its in vivo inhibitor Serpin B9. Granzyme B is a component of the
immune system that could be exploited for the design of recombinant con-
structs effective in cancer therapy. The work has been carried out in col-
laboration with Prof. Barth at Fraunhofer Institute, RWTH - University of
Aachen. Next, I have applied protein-protein docking procedures to explore
the possible binding poses between PARP10 and GSK3β, two interacting
proteins involved in cancer pathways. This work is in collaboration with
Prof. Lu¨scher at the Clinics of RWTH Aachen University. Finally, in close
collaboration with Dr. Adriana Pietropaolo (U. Catanzaro, Italy), I have
investigated the conformational flexibility of the complex between the neu-
rotrophin NGF, essential for neuron function and survival, and its receptor
TrkA. This complex is relevant for Alzheimer’s therapy. The results show
that the structure of the complex in solution may differ from that in the
solid state (so far the only one available). The previously unrecognized
structural information could be used to design of new NGF mimics and
signaling modulators in Alzheimer’s therapy.
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1Introduction
Protein-protein interactions maintain and regulate most processes in the cell, from
metabolism to transcription, from growth, to differentiation and programmed cell death
(1, 2, 3). System biology approaches1 allow to predict a variety of properties of the re-
sulting interactomes. Indeed, the systematic protein-protein interaction mapping, when
coupled with experimental validation, provides insights into the properties of complexes
integrated into their biological networks, as well as into the disease mechanisms at a
system level (10). A remarkable result in this regard just appeared while writing this
thesis. A whole-cell computational model of the human pathogen M. genitalium (11)
turned out to account for all of the annotated gene functions and the related experi-
mental data. This very recent achievement clearly shows that computations are greatly
advancing our understanding of complex cellular behaviors (11).
In spite of its successes, however, the applicability and predictive power of systems
biology is often limited by the lack of structural information (12). Indeed, because of
the limitations of the experimental structural techniques (13)2, a significant fraction of
protein/protein complexes is expected to be extremely difficult to study and/or highly
time consuming, using classical structural methods (16). In this context, using efficient
1These approaches are based on data coming from several experimental sources, including yeast-two
hybrid systems (4), mass spectrometry (5), colocalisation (6), analysis of gene fusion (7), phylogenetic
profiling (8) and co-evolution (9).
2Structural information at low-to-intermediate resolution by mass spectrometry, cryo-electron mi-
croscopy, and small-angle X-ray scattering (14) is usally complemented by high resolution NMR spec-
troscopy and X-ray crystallography methods (15).
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computational approaches for protein complex structure predictions is crucial (17). In
particular, when the structural determinants of two interacting proteins are known,
computational docking represents a valuable strategy to predict the structure of their
complex (18, 19, 20, 21, 22). In docking procedures, it is of enormous help to include
experimental data (obtained for example from molecular biology (23) and NMR studies
(24)) to guide the calculations. At times, it is also very useful to use template-based
prediction algorithms, recently developed on the basis of known structural complexes,
which combine structural similarity and evolutionary conservation in protein interfaces
to infer structural details of uncharacterized complexes (25). Conversely, when the
structure of the complex is known, one can use computational methods such as the
identification of surface residues by combining structures with sequence alignments
and phylogenetic trees (26, 27) or the comparative analysis of ’hot spots’ identified by
alanine scanning (28) to identify the determinants of protein interactions. Advanced
molecular-dynamics based methods such as free energy calculations (29) have also made
significant progresses in the past few decades (30), allowing one to describe the ener-
getics of protein/protein complexes.
In this work, we have applied state-of-the-art computational approaches to challeng-
ing systems of pharmaceutical relevance, from innovative therapeutic strategies against
cancer to protein/protein complexes playing a role for Alzheimer’s disease.
In the context of anti-cancer therapy, I first investigated the interaction between
human Granzyme B, a protein involved in immune-mediated apoptosis and thus rele-
vant in the control of cancer development, and its in vivo inhibitor Serpin B9 (31). By
predicting first the structure of Serpin B9 and then that of the complex (Fig. 1.1), I
identified the structural determinants of this interaction to rationally design Granzyme
B mutants. These featured a significantly decreased binding to Serpin B9 and an enzy-
matic activity comparable to that of the wild-type isoform. These mutants have been
expressed by our collaborators, in the group of Prof. S. Barth at Fraunhofer Institute
for Molecular Biology and Applied Ecology at RWTH - University of Aachen. They
may be exploited for the design of recombinant constructs of therapeutical relevance
able to specifically target tumor cells.
2
Figure 1.1: Granzyme B-Serpin B9 complex. Predicted complex between Granzyme
B (white surface) and Serpin B9 (pink surface).
We next turned our attention to the interaction between the PARP10 and GSK3β
proteins. Both are involved in cancer pathways, the first one by adding one ADP-ribose
moiety on specific targets and thus promoting DNA repair (130), and the second one
by modulating cell death through the interaction with key transcription factors such
as c-MYC (33). Unlike most of the other members of its protein family, PARP10 lacks
a glutamate of the characteristic catalytic triad ”HYE” in the active site. Therefore,
PARP10 likely acts by exploiting an exposed acidic residue of its interaction partner
to carry out the enzymatic reaction (34). The involvement of lysines and/or arginines
was also proposed (35, 36). We applied a protein-protein docking procedure to screen
all of the possible GSK3β acidic and/or basic surface residues which may interact
with PARP10 (Fig. 1.2). This study has been carried out in collaboration with the
experimental group of Prof. B. Lu¨scher at the Medical School of the RWTH Aachen
University. The results, although still preliminary, represent a step forward in the
understanding of PARP10 mode of action.
Our final study is of relevance for Alzhemer’s therapy. Here I provided a quantitative
description of the energetics of a protein/protein complex in aqueous solution. This
part has been carried out in close collaboration with Dr. A. Pietropaolo (University
of Catanzaro, Italy). I focused on the nerve growth factor (NGF), a secreted protein
which is crucial for neurons growth and survival, and its receptor TrkA (37). The
3
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Figure 1.2: GSK3β structure. The exposed residues considered as potential PARP10
interactors are represented in green sticks.
NGF/TrkA downstream signaling has been involved in Alzheimer’s disease pathogenesis
(38). Indeed, the so-called trophic action exerted by NGF (and possibly also by other
neurotrophins) in the target neurons has been shown to be actually the result of an anti-
amyloidogenic activity, in that the NGF signaling interruption leads to an increased
production of amyloid beta peptide (Abeta) associated to TrkA and to its intracellular
aggregation (39). The structure of NGF in complex with TrkA has been solved by
X-ray crystallography (40). Our calculations show that conformers other than that
found in the X-ray structure are present in aqueous solution (Fig. 1.3).
These structures provide a molecular basis for molecular biology data and could be
used for the rational design of TrkA signaling modulators with an improved accuracy.
4
Figure 1.3: NGF/TrkA conformers. NGF/TrkA conformers present in aqueous solu-
tion according to our calculations. The two TrkA chains are in blue and red cartoons, the
two NGF chains in grey and orange cartoons.
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2Molecular medicine topics
investigated in this thesis.
2.1 Cancer
Cancer is a leading cause of death worldwide and accounted for 7.6 million deaths (13%
of all deaths) in 2008 (41). It is a multi-factorial disease. Enviromental pollutants, in-
fections and incorrect lifestyles may directly damage genes or combine with existing
genetic faults within cells to cause the disease. A small percentage of cancers, approxi-
mately 5-10%, are entirely hereditary (42, 43). Its essential hallmarks are uncontrolled
cell survival, growth, angiogenesis and metastasis (44).
Classical therapeutic strategies are represented by surgery, radiotherapy and chemother-
apy. Novel strategies include: i) hormonal therapy, i.e. the use of drugs to block the
effects of hormones used by the cancer to grow (45); ii) angiogenesis inhibition, achieved
with the use of drugs inhibiting the growth of new blood vessels that could feed tumors
(46); iii) immunotherapy, based on the activation of patients immune system at a mul-
tistep level (promoting the production of protective T-cell responses and overcoming
immunosuppression in the tumour bed) (47); iv) targeted therapy, which uses drugs
specifically directed against well-defined targets that are critical for tumor survival and
not compromising for normal organs and tissues (48).
The last two strategies represent the background of the biological systems studied in
this thesis.
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2. MOLECULAR MEDICINE TOPICS INVESTIGATED IN THIS
THESIS.
2.1.1 Immunotherapy: immunotoxins
Immunotoxins (ITs) represent a very promising class of antitumor agents, being com-
posed of a targeting moiety (a specific ligand or monoclonal antibody) linked to a
cytotoxic moiety (49, 50). ITs bind to a surface antigen on a cancer cell, enter the cell
by endocytosis, and kill it (Fig. 2.1) (49).
Figure 2.1: An example of immunotoxin. The IT DAB389IL2 is composed of the ac-
tive and translocating domains of diphtheria toxin (DT) fused to human interleukin 2 (IL2).
The immunotoxin binds with cell-surface IL2R and then enters cells. In the cytosol, DT
modifies elongation factor 2 (EF2) by adenosine diphosphate (ADP)-ribosylation, which
leads to inhibition of protein synthesis and cell death. From (49).
Currently used ITs are derived from various plant and bacterial components, that
are then genetically fused or chemically conjugated to ligands that bind to cancer cells
(51, 52).
Hence, while in hematologic malignancies the immune system has been damaged, and
several cycles of IT therapy can be given without antibody formation, patients with
solid tumors and normal immune system may develop antibodies preventing retreat-
ment (53). Non-specific toxicity leading to vascular leak syndrome has also been re-
ported (54). In order to overcome these problems, a novel generation of ITs in which
8
2.1 Cancer
the cytotoxic moiety is an endogenous protein of human origin, like proapoptotic pro-
teins or RNase, are currently being developed (55).
In this work we focused on Granzyme B. This protein has been demonstrated to
be very effective in killing human tumor cell lines that are otherwise resistant against
many cytotoxic drugs, and it can easily be recombinantly expressed (56).
2.1.1.1 Granzyme B.
The principal event during the defence against virally infected and malignant cells
is the secretion of cytotoxic granules, which contain a variety of granule-associated
proteases. Among these proteases, granzymes, structurally related serine proteases,
play a significant role. Five different human granzymes are known so far (A, B, H, K and
M), each with unique expression patterns and substrate specificities (57). Granzyme B
(GB) is one of the most important and well-studied members of the human granzyme
family. It is stored as a macro-molecular complex with serglycin and perforin within
cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells (58, 59). Its apoptotic
activity includes both caspase-dependent and independent pathways and it is based
on the proteolytic cleavage of several downstream caspases, predominantly pro-caspase
3, as well as caspase-independent proteins like Bid. These events lead to cytochrome
c release and mitochondrial permeability (60, 61, 62, 63). Cytochrome c is a pro-
apoptotic factor that, together with HtrA2/OMI (which blocks inhibitors of apoptosis)
and endonuclease G (ENDOG; which activates DNA damage), is released after the
disruption of the outer mitochondrial membrane by truncated Bid. It then binds to
APAF1, which recruits pro-caspase-9 to form the apoptosome. In the apoptosome,
pro-caspase-9 is activated and in turn proteolytically activates caspase-3 1 (Fig. 2.2).
Caspase 3, finally, is responsible for DNA fragmentation in apoptosis (65).
GB also disrupts the mitochondrial transmembrane potential through an unknown
mechanism and cleaves ICAD (inhibitor of caspase-activated DNase) to free CAD to
directly cause DNA fragmentation (64).
1Partially activated pro-caspase-3 can also dimerize and activate itself (64).
9
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THESIS.
Figure 2.2: Mechanism of action of GB. It enters the cytosol by a mechanism involving
perforin and acts through two targets, BID and pro-caspase-3. From (64).
The GB crystal structure has been resolved (66, 67). As in other serine proteases
(67), the granzyme B structure is folded into two six-stranded β-barrels connected by
three trans-domain segments, and the three catalytic residues, His 44, Asp 88 and
Ser 183, are located at the junction of the two β-barrels with the active site cleft
perpendicular to this junction (66) (Fig. 2.3).
10
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Figure 2.3: GB structure. The two β-barrels are represented in yellow and orange
cartoon, the three catalytic residues in cyan sticks.
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THESIS.
2.1.1.2 Serpin B9.
GB-mediated immune responses are in many tumor cells evaded by the cytosolic ex-
pression of Serpin B9 (SB9) (68, 69, 70). SB9 is a member of the serpin superfamily, an
ever-expanding group of structurally related proteins, which regulate proteases of the
classical and innate complement system within vertebrates (71). This 42 kDa protein
has been shown to irreversibly inactivate GB (68, 72, 73). This natural GB inhibitor is
initially expressed in cytotoxic T lymphocytes and natural killer cells but it is absent
from cytotoxic granules. It can protect cells from misdirected GB (73, 74).
It has been proposed that certain tumours up-regulate SerpinB9 as a mechanism of im-
mune evasion (69, 75, 76, 77). This reduces the GB potential for immunotoxin-based
therapeutic application (78, 79, 80, 81).
Mammalian serpins are characterized by a common serpin fold, consisting of 350-400
amino acids, three β-sheets and eight or nine α-helical linkers (82). Moreover, a highly
flexible peptide loop, known as the reactive centre loop (RCL), holds the reactive centre
(Fig. 2.4).
The RCL peptide bond that is attacked by the interacting protease is denoted
P1-P1’ (84) where P1 is N-terminal and P1’ is C-terminal to the site of cleavage.
Interaction with the target protease via an ester bond at P1 (85) results in a dramatic
conformational change where the RCL is inserted as a middle strand in the central
beta-sheet. This change distort and inactivates the interacting protease (83).
12
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Figure 2.4: Typical serpin fold. RCL is represented in yellow, the central beta-sheet
in red. From (83).
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THESIS.
2.1.2 Targeted therapy: PARP inhibitors.
A targeted antitumoral therapy that has generated significant interest is the selective
cytotoxicity of poly(ADP-ribose) polymerase (PARP) inhibition in tumor cells (86).
PARPs, also referred to as diphtheria toxin-like ADP-ribosyltransferases (ARTDs) (87),
constitute a multi-gene family of 17 enzymes involved in a number of cellular processes
including DNA damage detection and repair, chromatin modification, transcription and
cell death pathways. These processes are critical for many physiological and patho-
physiological outcomes, including genome maintenance, aging, inflammation, neuronal
function and carcinogenesis (88). PARPs’ vital role in DNA repair makes them an
attractive antitumor target (89).
2.1.2.1 PARPs structure and function.
PARPs are multi-domain proteins, which include: (1) an amino-terminal double zinc-
finger DNA binding domain; (2) a central automodification domain, which is responsible
for releasing the protein from the DNA after catalysis and (3) a carboxyl-terminal
NAD+ binding catalytic domain (90, 91, 92). The latter is a conserved domain that
contains the ”PARP signature” motif, a highly conserved sequence (100% conserved in
PARP-1 among vertebrates) that forms the active site (91, 93).
PARPs act by catalyzing the polymerization and attachment of ADP-ribose units from
NAD+ onto specific amino acid residues of selected protein substrates (93). In response
to stimuli such as a metabolic, chemical, or radiation-induced DNA single-strand break
damage, PARPs hydrolyze NAD+, releasing nicotinamide and one proton, and catalyze
the successive transfer of the ADP-ribose moiety to nuclear protein acceptors that might
be transiently inactivated. The reaction is initiated by the formation of an ester bond
between the amino-acid acceptor (Glu, Asp or COOH-Lys) and the first ADP-ribose.
Polymer elongation involves the catalysis of a 2’-1”-glycosidic bond (Fig. 2.5) (94).
The up to 500-fold rise in poly(ADP-ribose) synthesis translates DNA damage into
intracellular signals that trigger DNA repair and/or cell death pathways (95).
However, some PARP enzymes have mono-ADP-ribose transferase (mART), not
ADP-ribose polymer synthase, activity (96). Evidence for this is strong for ARTD8
(PARP14) and ARTD10 (PARP10) but uncertain for other family members, due to
the lack of known substrates to study the functions of these enzymes (97).
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Figure 2.5: Poly-ADP-ribose formation by PARPs. Adapted from (94).
Before the PARP14 and PARP10 characterization, only extracellular enzymes and bac-
terial toxins were thought to mono-ADP-ribosylate protein targets (98).
In this thesis one of the proteins studied is PARP10, hence in the following section
I will describe it more in detail.
2.1.2.2 PARP10.
PARP10 was first identified as a protein interacting with c-MYC, a proto-oncoprotein
deregulated in the majority of human cancers that functions as a transcriptional regu-
lator and controls cell proliferation, differentiation, and apoptosis (99).
It is a ubiquitously expressed protein that shuttles between nuclear and cytoplasmic
compartments (98) and has auto-ADP-ribosylation activity (100).
On the basis of homology to PARP1 (the best characterized member of the PARP
family), PARP10 was expected to function as a poly-ADP-ribose polymerase, whereas
it was then identified as a mART with no polymerase activity (34). A comparison of
the PARP10 catalytic domain with PARP1 shows that core structural elements such
as the NAD+-binding residues are conserved, but the general domain organization is
significantly different (Fig. 2.6) (98).
In particular, the PARP1 H887 and Y919 are involved in NAD+ binding and con-
served in PARP10 and other PARPs. On the contrary, the catalytic glutamate that
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Figure 2.6: Comparison between PARP1 and PARP10 structural organization.
PARP1 contains three zinc-finger domains (Zn I, II and III), a breast cancer suppressor
protein-1 domain (BRCT), a WGR domain (named after a conserved sequence motif), a
PARP regulatory domain (PRD) and the catalytic PARP domain. PARP10 consists of a
RNA recognition motif (RRM), a glycine-rich region (GRD) and three ubiquitin-interaction
motifs (UIM), in addition to its catalytic mono-ADP-ribosyltransferase (mART) domain.
From (98).
defines the enzymatic polymerase activity of PARP1 (E988) is missing in PARP10 as
well as in PARP12, and is replaced by an isoleucine (Fig. 2.7) (34).
Figure 2.7: Structure-based sequence alignment of PARP1, PARP3, PARP10,
and PARP12 catalytic domains. Yellow shadings indicate structurally conserved
regions. Asterisks indicate the residues of the conserved ”HYE” triad. PARP12 and
PARP10 catalytic glutamates are replaced by an isoleucin. From (34).
Thus, an alternative substrate-assisted catalytic mechanism was proposed, in which
the acidic target residue of the substrate functionally substitutes for the catalytic glu-
tamate to transfer ADP-ribose. This mechanism explains the fact that PARP10 can
only mono-ADP ribosylate its protein substrate (34).
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GSK3β. Glycogen synthase kinase-3 (GSK-3), a protein-serine kinase implicated in
cell differentiation, phosphorylates several regulatory proteins that are activated by
dephosphorylation in response to hormones or growth factors (101). There are two
mammalian GSK isoforms encoded by different genes and called GSK3α and GSK3β,
which share 85% of sequence identity (102). GSK3β was first identified as a critical
mediator in glycogen metabolism and insulin signaling, but it is now known to be an
important component of several pathways involved in protein synthesis, cell prolifer-
ation and differentiation (103). GSK3β also participates in neoplastic transformation
and tumor development. Its role in tumorigenesis and cancer progression remains con-
troversial; it may function as a ”tumor suppressor” for certain types of tumors, but
promotes growth and development for some others. GSK3β also mediates drug sensi-
tivity/resistance in cancer chemotherapy (104).
Human GSK3β is a 46-47 kDA protein consisting of 433 amino acids. The structure
consists of the typical two-domain kinase fold (105) with a β-strand domain at the
N-terminal end and a α-helical domain at a C-terminal end. At the interface of the
α-helical and β-strand domain, a ATP-binding site is bordered by a glycine-rich loop
and a hinge domain (Fig. 2.8) (106).
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Figure 2.8: GSK3β structure. From (106).
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Phosphorylation of Tyr216 increases the catalytic activity, even if it is not strictly
required for substrate phosphorylation, while GSK3β phosphorylation at Ser9 in N-
terminal region leads to inhibition of its kinase activity (107).
GSK3β has been already found to interact with PARP1 in the regulation of oxidative
cell response (108) and with PARP5a (tankyrase) during mitotic progression (109). Un-
derstanding the structural details of the GSK3β-PARP10 interaction may be therefore
important to develop new therapeutic agents.
2.2 Neurotrophins in neurodegenerative disorders.
Neurotrophins constitute a family of closely related proteins that were identified initially
as survival factors for sensory and sympathetic neurons. They promote and regulate
the survival of neurons in the vertebrate nervous system and control their development
and function (110, 111).
Alterations in neurotrophin levels have been implicated in neurodegenerative disorders
such as Huntington’s (112) and Alzheimer’s (113) disease.
Because of their crucial role for the regulation of synaptic connections and synapse
structure, neurotransmitter release and synaptic plasticity, neurotrophins have been
studied as possible therapeutic strategies to reduce neuronal degeneration (114, 115,
116, 117, 118, 119, 120).
Neurotrophins family includes the Nerve Growth Factor (NGF), the Brain-Derived
Neurotrophic Factor (BDNF), the Neurotrophin-3 (NT-3) and the Neurotrophin-4/5
(NT-4/5) (121, 122). The actions of neurotrophins depend on two different transmembrane-
receptor signalling systems (123): the tropomyosin kinase receptors (Trk) and the p75
neurotrophin receptor (p75NTR), a member of the Tumor Necrosis Factor (TNF) re-
ceptor superfamily (122, 124).
All neurotrophins bind with similar affinity to p75NTR and selectively to specific
Trk receptors, each of them activates several signal transduction pathways (125). NGF
binds preferentially to TrkA, BDNF and NT4 to TrkB and NT3 to TrkC (Fig. 2.9).
The affinity can be regulated by receptor dimerization, structural modifications or
association with the p75NTR (126). The p75 receptor can bind to each neurotrophin,
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act as a co-receptor for Trk receptors, increase the affinity of TrkA for NGF and enhance
its specificity for cognate neurotrophins (127).
Figure 2.9: Neurotrophin receptors. Neurotrophins binding to two classes of recep-
tors: the low affinity receptor p75NTR and specifically to members of the Trk receptors
family. (b) Diagram of the receptors subdomains. Interactions between Trk and p75 re-
ceptors can lead to changes in the binding affinity for neurotrophins. From (128).
In the following paragraph I will describe further in detail NGF, the most charac-
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terized neurotrophin.
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2.2.1 The Nerve Growth factor
The Nerve Growth Factor (NGF) (129) plays a central role in the growth, survival
and maintenance of peripheral and central nervous tissues of both embryos and adults
(131). In addition, it has been characterized as a signaling molecule for nerve cells and
also for the neuroendocrine-immune systems (132, 133).
NGF exerts in vivo a number of effects on neuronal and non-neuronal cells (134), being
able to i) stimulate the development of sympathetic and sensory neurons (135); ii) guide
the nerve growth (136); iii) elicit growth and differentiation into mature cells not only
on sensory and sympathetic nerve cells but also on several populations in the central
nervous system (137).
An important feature of NGF is the retrograde transport. Indeed, NGF released
from target cells activates TrkA receptors on axon terminals and triggers activation
of PI3K/Akt, MEK/ERK, and PLC signaling pathways. The signal then travels ret-
rogradely along axon to cell body to promote neuronal survival (138). Moreover, NGF
triggers TrkA endocytosis through binding to TrkA and TrkA phosporylation, and the
endocytic TrkA might serve as the retrograde signal (139). The TrkA downstream
signaling molecules activated by NGF could also act as a retrograde signal (140).
NGF’s content in the brain decreases with age, particularly in memory-related areas
such as the hippocampus (141). Deficits in NGF release and TrkA phosphorylation sig-
naling have been shown to contribute to age-related decline in long-term potentiation
(142). On the other hand, NGF was shown in vivo to promote the repair of peripheral
nerve injury (143).
However, the therapeutic efficiency of NGF has been greatly limited by delivery prob-
lems and severe side effects due to a poor target selectivity (144, 145).
A promising strategy involves the use of peptide mimics, i.e. molecules rationally de-
signed by non-natural modifications of existing peptides to have an agonist or competi-
tive antagonist effect, which may be useful in the treatment of several neurodegenerative
diseases and nerve injuries (146, 147, 148, 149). Evidences of the possibility to success-
fully evaluate the stability of these designed complexes with the use of computational
tools have already been provided (150).
NGF mimics have been shown to exhibit neurotrophic effects by binding to TrkA
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(151, 152, 153, 154, 155, 156, 157). In this respect, the identification of structural
determinants of the NGF/TrkA complex (40) has represented a real breakthrough. In-
deed, a deep understanding of the molecular basis of NGF/TrkA molecular recognition
might provide important insights for drug design and protein inhibitors (128).
2.2.2 The NGF/TrkA structure.
NGF structure was first determined by X-ray crystallography in 1991 (158). It repre-
sents the prototype of a large family of neurotrophins and features a compact tertiary
structure based on a cluster of 3 cystine disulfides and 2 very extended, but distorted
beta-hairpins (159). It binds to p75NTR (see Appendix B) and TrkA receptors as a
dimer held together by non-covalent interactions (160).
The complete extracellular domain of TrkA complexed with NGF was also solved (40),
revealing a crab-shaped homodimeric TrkA structure (Fig. 2.10).
The NGF/TrkA structure is characterized by:
(i) a leucine-rich repeat (LRR), formed by three LRR units (D2), flanked by two
cysteine-rich domains (D1 and D3). Three leucine-rich repeats form the central part
of the D1-D3 body. Each repeats is featured by intrastrand hydrogen-bonded turns.
Each of the interstrand segments contains a half-turn of a α-helix. The LRR C-terminal
contains a 13-residues α-helix beginning and ending with short 310 helices (154-164 and
169-173). Moreover, it is stabilized by a salt bridge (Glu268-Lys133) and a hydrophobic
cluster (Trp132, Trp158, Ala155) surrounded by numerous van der Waals contacts;
(ii) Two immunoglobulin-like subdomains termed IgG-C1 and IgG-C2 (D4 and D5 do-
main, respectively), deemed relevant for NGF binding (161, 162);
(iii) Loop II of NGF, which was reported to have a role for NGF biological activity
mediated by TrkA receptor (163);
(iv) Six high-mannose-containing N-linked glycosylation sites (Asn95, Asn121, Asn188,
Asn262, Asn281, Asn358), which appear to play a role in the TrkA structural integrity,
as located at TrkA interdomain boundaries.
The secondary structure features of the TrkA in the NGF/TrkA complex include:
• a network of parallel β-sheet involving residues L48 to W144;
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Figure 2.10: Structure of Nerve Growth Factor Complexed with the Extra-
cellular Domain of TrkA. The TrkA ECDs are in orange and shown as ribbons with
transparent molecular surface, and NGF is blue-green and only shown as ribbons. N-linked
glycosylations observed in the structure are drawn as cyan surfaces. The approximately 32
amino acid connecting peptide linking the base of the Ig-C2 domain of TrkA to the cells
surface is drawn as dotted line. Adapted from (40).
• a short 310 helix involving residues C154 to L156 and an α-helix from R157 to
E165;
• a second network of β-sheet involving residues W195 to V278;
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• a third network of β-sheet involving residues F284 to A376;
• a short 310 helix involving residues H353 to N355.
The structural sections of NGF homodimer include instead:
• a α-helix involving residues P5 to R9;
• a loop-β-sheet involving residues E11 to C58;
• a long parallel β-sheet involving residues W76 to R114.
Zaccaro et al. (164) postulated an allosteric model of TrkA activation by large-
scale conformational changes. In this model, TrkA activation is a multistage process
involving Trk subdomains, where IgG-C1 subdomain is a hinge region regulating TrkA
conformation and activation.
It was already reported in the literature that tyrosine kinase receptors, to which TrkA
belongs, undergo conformational changes upon ligand binding (165). However, such a
model was argued by Wehrman et al. (40) in the case of TrkA, since the high structural
constraint in the NGF/TrkA complex.
In spite of its importance, only very few studies have been focused on the structure
and dynamics of NGF and its TrkA receptor (150, 166, 167) and all of them are focused
on selected segments of neurotrophins and TrkA.
Through Amber94 (168) -based MD simulations of human NGF-TrkA domain 5
(NGF/TrkA-D5) complex, Settanni et al. (166) found that highly persistent, water-
mediated H-bond interactions at the protein-protein interface are relevant for binding.
Both direct and water-mediated protein-protein contacts stabilize the complex. Berrera
et al. (150) addressed the specificity of NGF N-terminus segment by Amber94-based
MD simulations on the NGF/TrkA-D5 complex with or without the NGF N-terminus.
The complete complex is stable during the dynamics, but when N-terminus is missing,
the two moieties detach. More recently, Amber03 (169)-based MD simulations pointed
to the plasticity of the NGF(1-16) and NT-4(1-16) N-terminus peptides (167).
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A large amount of data including sequences and structures of several proteins is cur-
rently available. Two main computational approaches exist to predict structural deter-
minants and extract functional insights from these data: structural bioinformatics and
molecular dynamics.
Bioinformatics uses the statistical analysis of protein sequences and structures to under-
stand their function and to predict structures when sequence information is available.
Molecular modeling and atomistic molecular dynamics simulations use the principles
from physics and physical chemistry to study the function and folding of proteins.
Both approaches have been used in this thesis. Their fundamental principles are out-
lined in this Chapter.
3.1 Structural prediction from bioinformatics
3.1.1 Predictions for a single protein
3.1.1.1 Sequence alignment
Sequence alignment aims to match homologous characters that are descended from a
common ancestor (170). It can be applied to gene (nucleotides) or protein sequences
(aminoacids). The latter application may help to infer the evolutionary relation or also
the function of proteins.
The variation of protein sequences during the evolution may affect or not the protein
functionality. The mutation probability of each aminoacid into another depends on
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their physicochemical similarity. Thus, the alignments can be ranked by assigning a
substitution score (171, 172, 173, 174). Evolutionary events such as insertions and
deletions in the sequence represent one of the major sources of change at the molecular
level (175). These gaps are, however, less frequent events than mutations. They are
taken into account in sequence alignment algorithms through the application of gap
penalties (176).
Pairwise and multiple sequence alignments. Pairwise sequence alignment (177)
consists in maximizing a similarity measure between two sequences. The procedure
can be extended to any number of sequences, thereby defining an N-dimensional ma-
trix (178).
The two main classes of pairwise alignments are global alignments, which try to main-
tain a correspondence over the entire length of the two proteins, and local alignments,
where only the most similar part of the proteins are aligned. Hybrid methods, known as
semiglobal or ”glocal” (global-local) methods, attempt to find the best possible align-
ment by creating a map that transforms one sequence into the other while allowing for
rearrangement events (179).
Multiple alignments are more informative than pairwise alignments, since their re-
sults can be related to various protein structural features (180), but turn out to be
much more computational expensive than pairwise alignments (181). After the ad-
vent of large genome projects and the consequent explosion of sequence data in public
databases, the role of multiple sequence alignments has proved to be very important
not only for the identification of conserved motifs or key functional residues in a family
of proteins and in phylogenetic inference studies to define the evolutionary relationships
between organisms (182), but also to perform comparative multiple sequence analysis
at the genome level. This approach, instead of simply transferring annotation from one
sequence to another, analyses protein families and their evolution, as well as it detects
remote homologs (183). This information confers improved accuracy to most of the
computational methods used in proteomics, from gene identification and validation to
the determination of the protein 3D structure and the characterization of its molecular
and cellular functions (184).
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However, while the optimal solution to a pairwise alignment can be found within rea-
sonable time, multiple sequence alignments are significantly more computationally de-
manding. First of all, it is not straightforward to select the best scoring function
according to the phylogeny of the sequences. Hence, they are often assumed to be un-
related. Second, the computational cost of the possible use of dynamic programming
(see next paragraph) grows exponentially with the number of sequences.
A commonly used approach is therefore to do progressive alignment (185), where mul-
tiple alignments are built through the successive construction of pairwise alignments.
This permits to deal with a higher number of distantly related sequences. Progressive
methods are very dependent on the initial alignment and errors made at any stage of
the multiple alignment are propagated through to the final result. Thus, they are more
likely to perform well for closely related sequences, which may be seen as a limitation of
such methods. On the other hand, progressive methods provide a good compromise be-
tween time spent and quality of the resulting alignment, being efficient enough to deal
with more than 1000 sequences (182). In addition, many progressive methods that have
been developed in the last 15 years that are able to correct the biased selection of the
sequences by adding scaling factors weighted on the phylogenetic distance to their scor-
ing function (186, 187, 188, 189) or by including biological information, as in DIALIGN
(190) and ClustalW (191). The latter is the most widely used algorithm for multiple
sequence alignments, and it has been used in this work. The alignment is achieved
via three steps: pairwise alignment (calculating a distance matrix between each pair of
sequences), guide-tree generation (constructing a phylogenetic tree that represents the
genetic differences among the sequences) and progressive alignment from the nearest
to the farther sequences to obtain the multiple alignment (192).
Sequence alignment methods. The three main methods of aligning two protein
sequences are (186):
i) dot-matrix methods (193);
ii) dynamic programming (194, 195);
iii) word or k-tuple methods (196, 197).
(i) A dot matrix plot is created by placing one sequence on the horizontal axis and
the other on the vertical axis of the matrix. In correspondence of each entry of the
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matrix, a point is plotted if the horizontal and vertical elements are identical. If the
two sequences are identical, they will be described by a diagonal line in the center
of the matrix. The presence of features such as insertions and deletions (causing the
sequences to be of different length) leads the diagonal to be broken by empty squares.
Mutations and direct or inverted repeats are instead described by multiple lines plotted
in a various possibility of configurations (Fig. 3.1).
Figure 3.1: The dot matrix technique for sequence alignment. The correct align-
ment stands out because it forms a diagonal of continuous dots, broken at point mutations
and shifting to a different diagonal at indels. Adapted from (198).
(ii) The dynamic programming algorithm uses a substitution matrix to assign match
and mismatch scores to aminoacid pairs, and a gap penalty for matching an amino acid
in one sequence to a gap in the other. It analyzes this scoring matrix and finds the
highest scoring pathway (194) (Fig. 3.2). It consists of three main steps:
1. Initialization: a matrix with M+1 columns and N+1 rows is created where M and
N correspond to the size of the sequences to be aligned. Assuming that there is no gap
opening or gap extension penalty, the first row and first column of the matrix can be
initially filled with 0.
2. Matrix fill (scoring): One possible (inefficient) solution of the matrix fill step is based
on a procedure that assigns the maximal score Mi,j to each entry of the matrix starting
from the upper left corner. Mi,j depends on the scores associated to the entries to the
left, above and diagonal to i and j.
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3. Traceback (alignment): The traceback step determines the actual alignment(s) that
result a final maximum global alignment score. It takes the current entry and looks to
the optimal score neighbor cell among those which could be direct predecessors. There
are more alternative solutions each resulting in a maximal global alignment score, but
most dynamic programming algorithms will only print out a single solution.
Figure 3.2: An example of dynamic programming for two protein sequences.
The cells in the optimum path are showed in blue. Arrowheads are ”traceback pointers”,
indicating which of the three cases were optimal for reaching each cell. Some cells can
be reached by two or three different optimal paths of equal score: whenever two or more
cases are equally optimal, dynamic programming implementations usually choose one case
arbitrarily. Adapted from (199).
The method represents the heart of many well-known programs or their fast ap-
proximation (200).
(iii) Word methods, also known as k-tuple methods (201), are heuristic (i.e. experience-
based) methods that are not guaranteed to find an optimal alignment solution, but are
significantly more efficient than the standard dynamic programming-based methods
(i.e. the Needleman-Wunsch algorithm for global alignment and the Smith-Waterman
algorithm for local alignment). Word methods compare small sections, with some
minimum word length (k-tuples), of each sequence to begin the alignment instead of
comparing single letters.
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Scoring sequence alignments. The simplest way to score sequence alignments is
to count the number of identical residues in two aligned sequences and normalize by se-
quence length, which yields a percentage identity. However, this approach is too coarse
when applied to protein sequences, since it does not take into account two important
considerations: i) the different relative frequencies of the twenty amino acids. Certain
amino acids, such as alanine and leucine, are abundant, whereas others, such as trypto-
phan (W) and cysteine (C), are relatively rare. Thus, the conservation of a tryptophan
is statistically more significant than conservation of a leucine in a pairwise alignment;
ii) the chemical structures and functions of some amino acids, while not identical, may
be chemically similar and related (202).
Comparison tables, or matrices, are therefore used to attribute a score to any gene or
protein pairwise alignment. For protein sequence alignments, 20 x 20 matrices M are
used to evaluate all combinations of aminoacid pairs with a score M (a,b).
Several types of matrices have been proposed for protein sequences. Some are
based on a a priori estimation of physicochemical similarities. Others are based on
the probability of mutation over evolution. For example, PAM (Probability of Ac-
ceptable Mutation) matrices (203) are substitution matrices that encode the expected
evolutionary change at the amino acid level. Each PAM matrix is designed to compare
two sequences which are a specific number of PAM units apart. BLOSUM matrices
(204) are instead calculated by considering only blocks of amino acid sequences with
small change between them. They are based on a log-odds score calculated for each
of the 210 possible substitutions of the 20 standard amino acids, by counting the rel-
ative aminoacid frequencies and their substitution probabilities on a database of very
conserved regions of protein families, with no alignment gaps.
Large database searches. Sequence database similarity searching is one of the most
common computing techniques in modern biology. It allows the identification of se-
quences homologous to a known sequence, which is used to query large repositories of
DNA and protein information. This technique is extremely useful in the study of gene
and protein structure, function and evolution. In particular, it is commonly exploited
for gene identification, assigning a likely function to a gene or a protein and finding
relations among them. An example of application is the identification of a protein
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using the sequence of a short peptide fragment identified by biochemistry techniques.
However, typical similarity search programs must be especially configured to handle
short query sequences, as they are optimized for longer queries. Moreover, aligning a
whole sequence database with a query sequence is practically unmanageable with the
use of standard sequence alignment algorithms.
Thus, heuristic database similarity search programs such as FASTA (196) and BLAST
(197) have been developed, that use ’shortcuts’ in order to reduce the time required to
build an alignment that has a reasonable chance to be the best one (205).
FASTA. This algorithm (196) is divided into two steps. The first searches for highly
similar segments in two sequences. In this search, a word with a specific size is used
to identify regions shared by the two sequences with the highest density of identical
word matches. The second step is a Smith-Waterman alignment (195), consisting in the
search for optimal local alignments, that are discriminated through a scoring system
including a set of specified gap penalties. This alignment is centered on the diago-
nals that correspond to the alignment of the highly similar sequence segments. The
region for the Smith-Waterman alignment is bounded by a window size, which limits
the number of insertions or deletions one sequence can accumulate with respect to the
other sequence in the alignment. Finally, dynamic programming is used to join the
segments within this window. FASTA implementation typically use k-tuples of 1 and
2 for protein sequences (206).
BLAST. The BLAST algorithm (197) was developed to perform similarity searches
faster than FASTA. As the latter, BLAST also searches for k-tuples, but while FASTA
searches for all possible words of the same length, BLAST directly approximates align-
ments that optimize a measure of local similarity, the so-called maximal segment pair
(MSP) score (197) In practice, it achieves its speed by confining the search to the rare
words (occurring less frequently in protein sequences) that are most significant (186).
3.1.2 Homology modeling
Introduction. Homology modeling, known also as comparative modeling, is a com-
putational procedure for generating 3D models for proteins of unknown structure and
known sequence, based on the alignment with a homologous protein whose structure
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is known (template) (207). The proliferation of genome sequencing projects in the last
years has been rapidly widening the so-called ”sequence gap” between the number of
known protein sequences and the number of known protein 3-D structures leading to
an increased need for such a kind of technique (208).
Homology modeling is based on the knowledge that the protein structure is determined
by its aminoacid sequence, but it is better conserved than the sequence (209). There-
fore, proteins with similar sequences, even if distantly related, will fold into similar
structures, but also relatively different sequences can share structural similarities (Fig.
3.3). For pairs of distantly related proteins (sequence identity approximately 20%), the
regions with the same fold may comprise less than half of each molecule (210, 211).
Hence, a ”twilight zone” of 20-35% was defined, in which it is not possible to unam-
biguously distinguish between protein pairs of similar and non-similar structure (212).
Figure 3.3: Relation between sequence and structure homology. Two proteins
share the same 3D-structure when their sequence identity falls in the safe homology zone
(upper part of the picture). From (211).
.
The quality of homology modeling at the ”twilight zone” may therefore vary widely
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(213). These models may however be used to refine NMR structures, to find bind-
ing/active sites by 3D motif searching or to predict approximate biochemical function
(207). Generally, when the sequence identity exceeds 30%, reliable homology models
can instead be constructed (214).
Structural predictions. There are four main steps in constructing models (207):
template identification, target-template alignment and correction, model construction
(backbone generation, loop modeling, side-chain modeling and model optimization) and
model evaluation (Fig. 3.4).
Figure 3.4: Steps in comparative protein structure modeling. From (215).
Template identification. The selection of the template is the initial step. The se-
quence of the protein with unknown structure is used as a query for search of proteins
with known 3D structures in structural databases like the Protein Data Bank (216, 217).
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A possible template in the safe percentage identity zone (Fig. 3.3) can be identified
with programs such as BLAST (197) or FASTA (218). These programs work by calcu-
lating a series of pairwise sequence alignments between the target sequence and each of
the database sequences independently, and then providing a set of possible homologs
ranked by the scores (219).
Target-template alignment. Once the template is chosen, a pairwise sequence align-
ment has to be performed using a specific method, because database searching methods
do not give an optimal alignment. A specialized alignment method often employed is
the ClustalW program (191, 220).
The target-template alignment obtained must be then further improved manually. One
technique is to include the sequence of the template and the sequence to be modeled
in a multiple sequence alignment with other homologs.
Conserved regions in a multiple sequence alignment of homologous sequences often re-
fer to conserved structural regions, which can help to guide how the template sequence
should be aligned to the target sequence. Also, because the template structure reveals
what amino acids are located in the core of the protein (normally hydrophobic residues)
or on the surface (normally hydrophilic residues), this information can also guide the
alignment to correctly align physicochemically similar residues.
Model construction (backbone generation, loop modeling, side-chain modeling and
model optimization). Different programs such as MODELLER (221), SWISS PDB
Viewer (222), SCWRL (223) and web servers, such as 3D-JIGSAW (224) or SWISS-
MODEL (225) are available to build structural models of the proteins based on target-
template alignment. For the proteins modeled in this work, the program MODELLER
was used (221) because it has been reported to generate homology models characterized
by an improved stereochemical quality when compared with other automated programs
(226).
MODELLER is based on a technique known as satisfaction of spatial restraints,
by which a set of geometrical criteria are used to create a probability density function
for the location of each atom in the protein. The distance and dihedral angle spatial
restraints are combined with stereochemical restraints on bond lengths, bond angles,
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dihedral angles and nonbonded contacts based on CHARM22 (227) force field. The
probability density function restrains the CA-CA and backbone N-O distances, and
backbone and side-chain dihedral angles for different residue types. The generated
model violates these restraints as little as possible (228).
Insertions or deletions (gaps) in the alignment are placed out of helices and strands and
within loops and turns, but these elements are difficult to predict; moreover, template
and target may show quite different loop conformations (229). There are two main
approaches to loop modeling: i) Energy based: an energy function is employed, as
for true ab initio fold prediction. This is the approach exploited by MODELLER; ii)
knowledge based: one searches the PDB for known loops with endpoints that match
the residues between which the loop has to be inserted, and simply copies the loop
conformation (219).
Model refinement is a difficult task that requires an effective sampling strategy as well
as an accurate energy functional to guide the search through the conformational space.
Homology model refinement is primarily focused on tuning alignment and modeling
loops and side chains.
Recent attempts have been made to increase alignment accuracy but they are mainly
based on the use of physical chemistry energy information and MD simulations to refine
the whole model (230, 231, 232, 233, 234).
Model evaluation. Errors in a homology model may depend on i) the sequence
identity between target and template. If it is greater than 90%, the target structure
obtained can be compared to a crystallographically determined structure (210); ii) the
number of errors in the template. For homology models that have the correct fold, a
basic requirement is the stereochemical correctness. Some useful programs for evaluat-
ing stereochemistry are PROCHECK (235), PROCHECK-NMR (236), AQUA (236),
SQUID (237), WHATCHECK (238). The features of a model that are checked by these
programs include bond length, bond angles, side chain torsion angles, the location of
main chain conformation in acceptable regions of the Ramachandran map, the planarity
of side chain rings and of peptide bonds, a proper environment for hydrophobic and
hydrophilic residues, the absence of bad atom-atom contacts and of structural holes
(239). Based on these features, scoring functions such as the MolProbity clashscore
(240), and the PROCHECK G-factors (236) can help distinguishing between homology
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models of higher and lower accuracy (241).
Other evaluation methods assess the environment of each residue with respect to the
expected environment as found in the high resolution X-ray structures. These methods
are based on 3D profiles and statistical potentials of mean force (242) and are aimed
at finding structures/folds compatible with a given sequence. Programs implementing
this approach include Verify3D (243) and Anolea (244).
Ultimately, the validation of models comes from experiments such as site-directed mu-
tagenesis, circular dichroism, cross-linking, mass spectrometry, fluorescence-based ther-
mal shift, light scattering, molecular FRET or electron microscopy. Such experimental
data can be translated into constraints/restraints and introduced in the modeling pro-
tocols thus improving the accuracy of the models. Faster crosschecks are also possible:
for instance, with enzymes it is possible to verify the location of important catalytic
residues in the active site by comparison with homologous family members (245).
Since 1994, the biennial Critical Assessment of Structure Prediction (CASP) contests
(246) have provided an ideal opportunity to evaluate the accuracy of todays many
protein structure prediction methods. During each CASP season, about 200 research
groups try to predict the structures of more than 100 CASP targets. The target se-
quences are provided to CASP by structural biology laboratories just before the corre-
sponding structures are solved. The predictions are thus true blind predictions, allowing
performance to be measured on realistic test cases. CASP regularly shows that the ho-
mology modelling steps described above allow reliable models to be built in many cases,
from which a lot of structural and functional insights can be derived (247).
3.1.3 Protein-protein complex structural predictions.
3.1.3.1 Introduction.
Protein-protein docking methods can create models of protein complexes, provided
that the conformational changes upon association are restricted to the side chains (22).
However, it remains very challenging to account for backbone conformational changes
happening upon binding (22). Hence, most algorithms treat proteins as rigid bodies
or permit side-chain motion only, in order to reduce the search in the conformational
space (248). On the other hand, new promising approaches of flexible refinement,
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ensemble docking and explicit inclusion of flexibility during the entire docking process
are constantly being developed (249).
3.1.3.2 Multistep procedure in docking.
The general scheme of docking can be divided into four major stages (250):
1. Preprocessing stage: the proteins are analyzed to define their conformational space
and interaction surfaces. This process simulates the conformational selection model, in
which the conformational change in binding is thought to originate primarily from the
conformational diversity of the unbound state (251). The analysis of residues important
for the protein-protein interaction can be supported by user-provided bioinformatic or
experimental data.
2. Rigid docking : a set of solutions is generated including at least one near-native struc-
ture. This implies the possible occurrence of steric clashes, because proteins in their
unbound conformation can collide when placed in their native interacting position.
3. Refinement : each candidate is optimized by small backbone and side-chain move-
ments and by rigid-body adjustments. The resulting refined structures have better
binding energy and hardly include steric clashes. This stage models an induced fit
(252), a process where the initial interaction between a protein and a binding partner
induces a conformational change in the protein through a stepwise process (253).
4. Scoring : the candidate solutions are scored and ranked according to different pa-
rameters such as force-field based potentials, agreement with known binding sites, de-
formation energy of the flexible proteins, buried surface area and desolvation energy
terms. This stage is aimed to identify the near-native solutions among all the best-
ranked candidates.
In this work we used HADDOCK (High Ambiguity Driven protein-protein Docking)
algorithm (21, 254). Its docking protocol consists of three stages:
i) a rigid-body energy minimization;
ii) a semi-flexible refinement in torsion angle space;
iii) a final refinement in explicit solvent.
After each of these stages, structures are scored and ranked, and the best structures
are kept for the next stage (255). In particular:
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i) In the initial randomization step, the two molecules, A and B, are separated by 25
A˚ and randomly rotated around their center of mass. Then they are allowed to rigidly
rotate to minimize the intermolecular energy function. Two cycles of translational and
rotational rigid body minimization are subsequently performed, and the two molecules
are docked. The best structures in scoring term (tipically 200 structures) will proceed
to the second step.
ii) This step consists of a semi-flexible simulated annealing refinement in which the
side chains and the backbone at the interface are allowed to move, in order to take
into account some possible conformational rearrangements. This semi-flexible simu-
lated annealing (SA) consists of several stages: a) high temperature rigid body search
(2000K, 500 steps); b) rigid body SA (cooling step from 2000K to 500K, 500 steps);
c) semi-flexible SA with flexible side-chains at the interface (from 1000K to 50K, 1500
steps); d) semi-flexible SA with fully flexible interface, i.e. including both backbone
and side-chains (from 500K to 50K, 1500 steps). The resulting structures undergo then
steepest descent energy minimization.
iii) The final step consists of a gentle MD simulation refinement in a 8 A˚ shell of
TIP3P (256) water molecules of the remaining best structures (usually 200). During
this stage, the system is first heated to 300K, with flexible side-chains at the interface.
1500 molecular dynamics steps at 300K are performed, with a position restraint only
on non-interface heavy atoms. Finally the system is cooled down (1000 steps at 300,
200, 100K) imposing position restraints only to backbone atoms outside the interface.
Finally, the docking solution are clustered (based on pairwise backbone RMSD at
the interface) and sorted based on Haddock score. Clusters are analyzed and ranked ac-
cording to their average interaction energies (sum of electrostatic, van der Waals terms,
desolvation energy, Ambiguous Interaction Restraints (AIR) energy terms) and their
average buried surface area. The interaction energies are evaluated by full electrostatic
and van der Waals energy terms with a 8.5 A˚ distance cutoff using the OPLS (257)
force field.
To get accurate docking predictions, HADDOCK takes as input also bioinformatics
information, biochemical and/or biophysical experimental data, like mutagenesis data
or information about chemical shift perturbation upon binding. This information is
used to define the distance restraints that will be used along the docking of two up to
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6 biomolecules.
The Ambiguous Interaction Restraints (AIR) is a collection of restraints on two set of
residues, named active and passive residues, on the interacting surface. Active residues
are for example those detected by experiments (mutagenesis, chemical shift perturba-
tion upon complex formation) to make contact within the complex and solvent acces-
sible. Passive residues are their closest solvent accessible neighbors that potentially
make contacts. For every active residue, a single AIR restraint is defined between that
residue and all active and passive residues on the partner. An explicit AIR energy term
is introduced into the calculation with the functional form of a harmonic potential (be-
coming linear after a given cutoff distance) that depends on an effective distance. The
latter is calculated through the following formula:
deffiAB = (
Natoms∑
miA=1
NresB∑
k=1
Natoms∑
nk=1
1
d6mnk
)−
1
6 (3.1)
where m and n run over all the atoms of a given residue and k over the sum of
active and passive residues for a given protein. An upper limit to the effective distance
(typically 2 A˚) is enforced by Haddock (21). If this limit is exceeded, the AIR energy
becomes positive and the active residue experiences an attractive force towards the
active and passive residues of the partner molecule. If not, the restraint is satisfied and
the AIR energy and attractive force are zero for that restraint. Since many atom-atom
distances inversely contribute to the effective distance, an AIR restraint is typically
satisfied if a residue comes within 4-5 A˚ of any active or passive residue of the partner
molecule (258).
It is also possible to randomly remove a fraction of the AIRs, if the definition of inter-
acting residues is not clear. In this way, bad restraints could be discarded, allowing for
better docking solutions.
3.1.3.3 Model evaluation.
The PISA method (259) calculates the ∆G as the solvation free energy gain upon for-
mation of the predicted complex, in kcal/mol. The value is calculated as difference in
total solvation energies of isolated and interfacing structures. This prediction method
is validated by experimental measurements of solvation energies (259), and the values
obtained should be compared with the contribution from the interface interactions, i.e.
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mainly salt bridges (0.9-1.25 kcal/mol) (260), hydrogen bonds (0.6-1.5 kcal/mol) (261)
and at a lower occurrence disulphide bridges (2-8 kcal/mol) (262).
Alanine scanning methodology is aimed at measuring the effect of the deletion of an
amino acid side chain beyond the Cβ carbon atom on the affinity of a protein-protein
complex, thus allowing the identification of putative hot spots. Unfortunately, despite
significant advances in molecular biology, experimental alanine scanning still represents
a large effort that cannot be applied easily to a large scale screening of protein-protein
interfaces. Hence, a variety of computational approaches has been developed to detect
hot spots in modeled or experimentally determined protein-protein complexes for which
no experimental mutagenesis data is available (263).
In particular we used the Baker’s approach (28, 264). This method first defines the
interface residues as (i) residues that has at least one atom within a 4 A˚ radius sphere
of an atom belonging to the protein partner, or (ii) residues that becomes significantly
buried upon complex formation, as measured by an increase in the number of Cβ atoms
within a sphere with a radius of 8 A˚ around the Cβ atom of the residue of interest. The
program then replaces each of the interface residues individually with alanine residues,
and computes the effect of this mutation on the binding free energy of the complex,
allowing the identification of potential hot spots. This estimation relies on a simple
physical model. It uses all heavy atoms and polar hydrogens to represent proteins and
proposes a free energy function to linearly combine terms such as Lennard-Jones poten-
tials to describe atomic packing interactions, an orientation-dependent hydrogen bond
potential derived from high-resolution protein structures (265), Coulomb electrostatics,
and an implicit solvation model (266).
This model is validated by using mutational data for protein complexes from the Ala-
nine Scanning Energetics database (ASEdb) (267), a searchable database of binding
energy changes resulting from mutations of protein side-chain to alanine.
However, for the reliability of protein-protein docking results it is also crucial to
have an experimental validation. In most studies, models are selected and validated
using a variety of well-described methods able to provide some information on the
identity of interacting residues. These techniques include (268, 269): i) site-directed
mutagenesis (270); ii) fluorescence-resonance energy transfer (FRET) (271), used to
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determine the distance between labeled groups of interacting proteins; iii) chemical
crosslinking with subsequent mass spectrometric identication of the crosslinked peptides
after proteolytic digestion, a hybrid technique which appears especially well-suited to
capture information on residues involved in transient complexes (272, 273); iv) cross-
saturation coupled with NMR TROSY (transverse relaxation optimized spectroscopy)
experiments (274), which can be used for the identification of the interfaces of large
protein-protein complexes in solution (275, 276).
3.2 Physics-based methods: Molecular dynamics and free
energy calculations.
3.2.1 Introduction
Molecular dynamics (MD) is an important tool to understand the physical basis of the
structure and function of biological molecules. This computational method calculates
the time dependent behavior of a molecular system and is now routinely used to inves-
tigate the structure, dynamics and thermodynamics of biological molecules and their
complexes. Indeed, the early view of proteins as relatively rigid structures has been re-
placed by a dynamic model in which the internal motions and resulting conformational
changes play an essential role in their function (277).
In biophysics, the most widely used MD technique is the so-called classical MD. Such
method describes the atoms as point-particles by neglecting their internal structure,
and in particular the role of the electrons belonging to them. Such an approximation
results a completely adequate tool to describe the motion of any biologically relevant
system as far as chemical reactions are not involved in the mechanism we want to in-
vestigate.
Classical MD is based on Newton’s equation of motion, i.e. the atomic dynamic
trajectories are extracted by integrating the Newton’s second law:
~Fi = mi~ai with ~Fi =
δV (~r)
δ~ri
(3.2)
where ~ri is the position of the i-th atom, ~Fi the force acting on it, and V is the
potential energy of the system which is a function of the atom positions. The potential
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V that defines the interactions among the particles is described by a force field, i.e.
a particular functional form dependent on several empirical parameters obtained by
fitting experimental data or data coming from theoretical calculations based on high-
level (and computationally very expensive) quantum theories.
The ergodic hypothesis guarantees that thermodynamics information on the system
can be estimated as time averages, which equal the statistical ensemble average:
1
T
∫ ∞
0
A(t)dt = 〈A〉 (3.3)
In fact, for any system for which the ergodic hypothesis holds, we can say that
such system will eventually pass through all possible states if one allows the system to
evolve in time indefinitely. Therefore, in performing a molecular dynamics simulation
one needs to generate a longer and longer trajectory so that this equality is better and
better satisfied. In this case, experimentally relevant information concerning struc-
tural, dynamic and thermodynamic properties may then be calculated using a feasible
amount of computer resources (278).
In the typical MD algorithm cycle, the first step is to assign the initial velocities and
positions to each particle of the system. In the MD simulations used for the ’production
run’, the initial coordinates for a MD simulation usually comes from preliminary steps
such as an energy minimization, where a set of coordinates that minimizes the total en-
ergy of the system and satisfies any given constraint is found; when the temperature is
given, the initial velocities are usually randomly generated at the beginning of the sim-
ulation only constrained to satisfy the Maxwell distribution at that temperature. The
force acting on each particle is then calculated by using the chosen force field and the
position of all the other atoms. Any modern force field is formed by two parts that are
very different from the computational point of view: the short-range interaction and
the long-range interaction terms. The short-range interaction terms represent those
physical terms that becomes negligible when the particles come far apart. Therefore,
to save computational time, these terms are usually evaluated only for particles that are
within a certain fixed cutoff radius. The Newton’s equation of motion is then solved
by some integration method and finally the configuration of the system is updated.
The entire cycle just described is indefinitely repeated to produce the MD trajectory,
with the only difference in the initial step above where now the initial coordinates and
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velocities will be the updated coordinates and velocities obtained in the last step.
In this work, the NAMD simulation package (279) has been used. In the following
sections, the main MD integration algorithms and the functional form of the force field
are described.
3.2.2 Integration of the equations of motions.
MD simulations consist in the numerical, step-by-step solution of the classical equations
of motion (Eq. 3.1). The integration time step ∆t is chosen at the beginning of the
simulation and it remains unchanged during the run. The time step must be small
enough to allow describing the fastest motions of the system: ∆t ≤ 0.5 fs is normally
used when bond stretching have to be described. The fastest motions in a simulation
of biological systems will invariably involve the lightest hydrogen atoms (280). By
constraining these bonds to their equilibrium lengths using the LINCS algorithm (281),
a larger ∆t ≤ 1.5/2 fs can be employed while still retaining a good accuracy.
The most used algorithms for the integration of the equations of motions are the so-
called Verlet (282) and Leap-Frog (283) algorithms.
To derive the Verlet algorithm we start with the Taylor series of the position of a
particle around the time t and with the time step ∆t
~r(t+ ∆t) = ~r(t) +
d~r(t)
dt
∆t+
d2~r(t)
dt2
∆t2
2!
+
d3~r(t)
dt3
∆t3
3!
+O(∆t)4 (3.4)
The first order derivative of r(t) with respect to t is equal to the velocity. Similarly
the second order derivative equals to the acceleration, which can be substituted by the
force by using Newton’s second law. This reduces eq. 3.4 to
~r(t+ ∆t) = ~r(t) + ~v(t)∆t+
~F (t)
2m
δt2 +
d3~r(t)
dt3
∆t3
3!
+O(∆t4) (3.5)
and similarly we have
~r(t−∆t) = ~r(t)− ~v(t)∆t+
~F (t)
2m
δt2 − d
3~r(t)
dt3
∆t3
3!
+O(∆t4) (3.6)
Summing these two last equations and neglecting the higher order terms gives us
~r(t+ ∆t) ≈ 2~r(t)− ~r(t−∆t) +
~F (t)
m
∆t2 (3.7)
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where ~r(t+∆t) is the new position of the particle, ~r(t) its present position, ~r(t−∆t)
the position on the previous time step, ~F (t) the resulting force on the particle, and m
the mass of the particle. The Verlet algorithm does not use the velocity of a particle
to compute its new position.
The leapfrog algorithm can be derived from the Verlet algorithm. Leapfrog evaluates
the velocities at half-integer time steps, which are artificial points in time, exactly half
way between two time steps. Hence, to compute the new position, the algorithm uses
the velocities
~v(t− ∆t
2
) ≡ ~r(t)− ~r(t−∆t)
∆t
(3.8)
and
~v(t+
∆t
2
) ≡ ~r(t−∆t)− ~r(t)
∆t
(3.9)
Thus, assuming that the initial positions ~r(t) and velocity ~v(t− ∆t2 ) are known, the
steps to solve the equations of motions using the leapfrog algorithm are:
i) calculate ~F (t);
ii) calculate the new velocity ~v(t+ ∆t2 ) by exploiting ~v(t− ∆t2 ) and ~F (t);
iii) calculate the new position ~r(t+ ∆t2 ) by using eq. 3.9 with ~r(t) and ~r(v +
∆t
2 );
iv) repeat these steps until a stop criterium. The leapfrog method is however alge-
braically equivalent to Verlet’s algorithm, and, consequently, it gives identical trajec-
tories (278). However, there are some advantages in using the leapfrog scheme. The
algorithm is very stable and faster than Verlet; in addition, because of the symmetric
way in which it is defined, it is time reversible. This feature guarantees the conservation
of conserved quantities such as energy and angular momentum.
3.2.3 Force field.
A force field is a mathematical expression describing the dependence of the potential
energy U of a system on the coordinates of its particles. It consists of an analytical
form of the interatomic potential energy, U(r1 , r2 , . . . , rN ) and a set of parameters
entering into this form. The parameters are typically obtained either from ab initio
or semi-empirical quantum mechanical calculations or by fitting to experimental data
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such as neutron, X-ray and electron diffraction, NMR, infrared, Raman and neutron
spectroscopy, etc (284). In this work the AMBER parm99SB force field was used (285).
The AMBER functional form is:
U =
∑
bonds
1
2
kb(r − r0)2 +
∑
angles
1
2
ka(θ − θ0)2 +
∑
torsions
Vn
2
[1 + cos(nφ− δ)] +(3.10)
+
∑
impropers
Vimp +
∑
LJ4ij(
σ12ij
r12ij
− σ
6
ij
r6ij
) +
∑
elec
qiqj
rij
(3.11)
where the first four terms refer to intramolecular or local contributions to the total
energy (bond stretching, angle bending, and dihedral and improper torsions), and the
last two terms serve to describe the Van der Waals interactions (in this case by means
of a 12-6 Lennard-Jones potential) and the Coulombic interactions.
Bond stretching and angle bending are very often represented with a simple harmonic
function also in other force fields. A dihedral or torsional term is also required in any
molecule containing more than four atoms in a row. While angle bending, and bond
stretching, are often not relevant high frequency motions that can be replaced by a
rigid approximation, torsional motions are typically hundreds of times less stiff than
bond stretching motions and they are necessary to reproduce the major conformational
changes due to rotations about bonds and to correctly describe the local structure of
a macromolecule (286). Torsional energy is usually represented by a cosine function.
The parameters are usually derived from ab initio calculations and then refined using
experimental data such as vibrational spectra. The improper torsion term is needed
to ensure the planarity of some particular groups, such as sp2 hybridized carbons in
carbonyl groups or in aromatic rings, and describes the positive contribution to the
energy of those out-of-plane motions.
The last two terms describe the non-bonded intermolecular van der Waals and elec-
trostatic interactions. Van der Waals interactions between two atoms arise from the
balance between repulsive and attractive forces. Physically, the repulsion origins from
the overlap of the electron clouds of the atoms, while the interactions between induced
dipoles result in an attractive component that can be modeled with a r−6 term.
Concerning electrostatic interactions, while the molecular electronic density can be ob-
tained with a high accuracy by means of high-level quantum-mechanical calculations,
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the problem of reducing such density to a manageable description to be used in a
MD simulation is not trivial. The usual choice is to assign a partial atomic charge
to each nucleus and use Coulomb’s law to compute their contribution to the total en-
ergy. In particular, the dielectric constant is assumed equal to 1 (vacuum value), and
the restrained electrostatic potential model (287) is used to define partial atomic point
charges. In this model, charged are assigned to the atom-centered points so as to fit the
electrostatic potential derived from quantum chemistry calculation for a set of small
representative molecules.
3.2.4 Periodic boundary conditions.
In most cases simulations are not aimed to study isolated (in vacuo) particles, but the
bulk properties of a liquid or solid system. In particular, due to the importance of water
in connection with the properties of biological macromolecules, they are commonly
simulated in aqueous solution rather than in the gas phase.
However, standard simulations track only a small number of particles in order not to
slow down the computation. As a result, in these conditions most molecules would be
near the edge of the system, resulting in unrealistic surface effects.
For this reason, the imposition of some boundary conditions is required. With the
introduction of periodic boundary conditions (PBC), the simulation box is surrounded
by an infinite number of replicas of itself (Fig. 3.5). Only the N atoms inside the main
cell are considered explicitly, but as soon as one of the atoms leaves the cell, an image
particle enters from the opposite side to replace it.
Typically a cutoff radius is used for Lennard-Jones interactions of the order of 10 A˚.
If the potential range is not too long (the cutoff radius do not exceed half of the box
size), the minimum image convention is adopted in the calculation of the Lennard-
Jones term. This means that each individual particle in the simulation interacts only
with one atom, the closest one, among all its images.
In the case of macromolecules simulated in solution, their interaction with periodic
images would be an artifact and should be avoided. Thus, the length of each box
vector must exceed the length of the macromolecule in the direction of that edge plus
twice the cutoff radius.
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Figure 3.5: Schematic representation of periodic boundary conditions in 2D.
The figure shows a selected molecule in the primary cell together with 8 replicas. The
colored molecules represent those being at a distance from the reference molecule smaller
than the cutoff radius. Typically the cutoff is applied to full molecules (for example using
the distance between their center of masses as reference) or neutral groups, in order to
minimize truncation effects. (Taken from (286)).
3.2.5 Neighbors list.
The computation of the short-range van der Waals terms in eq. 3.11 involves, in prin-
ciple, a large number of pairwise calculations. However, only a relatively small number
of pairs are within the cutoff radius for the van der Waals interactions. Therefore, in
order to speed up the simulation, a neighbors list is commonly employed.
Namely, in a system composed of N atoms, for each atom i the distances with the
remaining N-1 atoms are calculated. The short-range non-bonded contribution to the
total force acting on i is due only to the atoms within a sphere of a certain radius Rc
from the atom i. A list of all of the atoms that are at a distance smaller than Rc+∆list
is created for each atom i, where ∆list is a value chosen by the user (typically ∼ 1-2 A˚).
At each time step, the search for the atoms situated at a distance ≤ Rc of a given atom
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is done only over the atoms included in its neighbor list. The list is updated regularly
but only after a certain number of step (e.g. 20) to take into account the atoms that
enter or leave the sphere.
3.2.6 Long range interactions.
An interaction between to atoms is defined long-range when the corresponding force
falls off to zero no faster than r−d, where d is the dimensionality of the system (d=3 in
common biological cases). In recent years, a number of methods have been introduced
which allows the inclusion of long-range electrostatic interactions in molecular dynam-
ics simulations. For simulations of proteins and enzymes in a crystalline state, the
Ewald summation is considered to be the best treatment for long-range electrostatic
interactions (288). Some approximated but numerically faster variations of the Ewald
summation method include the particle-mesh Ewald method (289) that is employed in
the NAMD program.
3.2.6.1 Ewald sum.
The Ewald sum (290) is a method to sum up electrostatic interactions in an infinite
lattice, or, alternatively to compute electrostatic interactions under periodic boundary
conditions. The potential energy can be written as
V =
1
2
∑
(
1
4pi0
N∑
i=1
N∑
j=1
qiqj
rij , n
) (3.12)
where qi and qj are the charges, n is the index of the periodic box and rij is
the distance between the charges i and j in the n-th box. Unfortunately, this sum
converges slowly with n and therefore a very large number of images is required to
achieve a reliable estimation of the potential energy. The idea behind this method is
to:
i) surround each ion with a Gaussian charge distribution of opposite sign and equal
magnitude to screen the interactions so that they are short-ranged (and the sum of
interactions is now absolutely convergent):
ρGi (r) = qi(
α
pi
)
3
2 exp(−α|ri + nL|2) (3.13)
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where α, the width of the Gaussian distribution, is an arbitrary parameter that can
be adjusted to optimize the convergence rate;
ii) add a neutralizing charge distribution so that the overall potential becomes identical
to the original one;
iii) calculate the contribution to the electrostatic potential of this this neutralizing
distribution in the reciprocal space where it is absolutely convergent and therefore
both the terms, the short range one in ii) and this one, will be absolutely convergent
and suitable for a numerical treatment.
3.2.6.2 Particle Mesh Ewald.
The particle mesh Ewald (PME) approach allows a fast calculation of the electrostatic
energy in PBC, using the profound advantages of the fast Fourier transform (FFT) for
calculating discrete Fourier transforms. When a fixed cutoff is applied to the direct
Ewald sum, the number of terms needed in the reciprocal sum is O(N). Since each
such term is nominally of order N to calculate, the reciprocal sum is O(N2). Similarly,
the discrete Fourier transform of N coefficients is an order N2 calculation. However,
the FFT performs this task in O(N)logN operations. All the particle mesh-based
approaches reduce the calculation of the reciprocal sum to a sum over coefficients of the
discrete Fourier transform of a gridded charge distribution, which is then accelerated
to an O(N)logN calculation using the three-dimensional FFT (291). Therefore, the
PME algorithm is particularly suited to simulate Coulombic electrostatic interactions
of periodic systems with a large number N of atoms.
3.2.7 Temperature and pressure control.
MD simulations can be carried out in different thermodynamic ensembles, characterized
by the control of certain thermodynamic quantities. The simplest is the microcanonical
ensemble (NVE), in which the number of particles, the volume and the total energy are
conserved. However, the microcanonical ensemble does not correspond to the ensemble
in typical experimental conditions. A more meaningful description of the physical sys-
tem is achieved by simulating the system at varying energy but with pressure and/or
temperature that are kept constant. These are called canonical (NVT) or isothermal-
isobaric (NPT) ensembles. In these simulations, thermostat and barostat algorithms
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(the main ones are described below) are required to control the temperature and pres-
sure of the system during the MD run. In this work the Nose-Hoover thermostat and
barostat are adopted (292, 293).
3.2.7.1 Berendsen thermostat.
Experimentally, to maintain the temperature, the system is coupled to an external heat
bath with fixed temperature T0. In the Berendsen approach, the thermostat behavior
is mimicked by rescaling the velocities of the particles at each step, such that the rate
of change of temperature is proportional to the difference in temperature:
dT (t)
dt
=
1
τ
(T0 − T (t)) (3.14)
where τ represents the coupling parameter which determines how tightly the bath
and the system are coupled together. This method gives an exponential decay of the
system towards the desired temperature. The change in temperature between successive
time steps is
∆(t) =
δ(t)
τ
(T0 − T (t)) (3.15)
Thus, the scaling factor for the velocities is
λ2 = 1 +
δ(t)
τ
T0
T (t− δ(t)2 )
− 1 (3.16)
The δ(t)2 term is due to the fact that the called leap-frog algorithm is used for the
time integration.
In practice, τ is used as an empirical parameter to adjust the strength of the coupling.
Its value has to be chosen with care. In the limit τ →∞ the Berendsen thermostat is
inactive and the run is sampling a microcanonical ensemble. The temperature fluctu-
ations will grow until they reach the appropriate value of a microcanonical ensemble.
However, they will never reach the appropriate value for a canonical ensemble. On
the other hand, too small values of τ will cause unrealistically low temperature fluc-
tuations. If τ is chosen the same as the timestep δ(t), the Berendsen thermostat is
nothing else than the simple velocity scaling. Values of ∼ 0.1 ps are typically used in
MD simulations of condensed-phase systems.
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3.2.7.2 Nose-Hoover temperature coupling.
The extended system method introduced by Nose and subsequently developed by
Hoover (292, 293) turns out to be more efficient for sampling a correct canonical en-
semble than the Berendsen thermostat, which is instead suitably used for relaxing a
system to a target temperature.
The idea of the Nose-Hoover thermostat is to modify the equation of motions to in-
clude a non-Newtonian term in order to maintain the total kinetic energy constant.
This term is a friction factor used to control particle velocities. This friction factor is
actually the scaled velocity, v(ξ), of an additional and dimensionless degree of freedom
ξ. This degree of freedom has an associated ”mass”, which effectively determines the
strength of the thermostat. The equations of motions obeyed by this additional degree
of freedom guarantee that the original degrees of freedom sample a canonical ensemble.
3.2.7.3 Langevin thermostat.
In the Langevin thermostat (294), an additional friction force β and a small random
thermal noise term ηi extracted from a Gaussian distribution are added to the velocity
of each system particle:
~ri(t) =
~Fi
mi
= β~ri(t) + ηi(t) (3.17)
These two factors are balanced in order to give on average a constant temperature.
3.2.7.4 Berendsen barostat.
The Berendsen algorithm to control the pressure of the system is similar to the Berend-
sen temperature coupling. In this case, the system pressure is set toward a desired value
by changing the dimensions of the simulation cell size during the simulation. An extra
term is added to the equations of motion that effects a pressure change:
(
dp
dt
)bath =
p0 − p
τp
(3.18)
where τp is the time constant for the coupling. A simple proportional coordinate
scaling, concomitant with volume scaling, minimizes local disturbances.
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3.2.7.5 Nose-Hoover / Langevin piston.
The pressure control schemes used in this thesis is the Nose-Hoover / Langevin piston
implemented in NAMD (279). This method should be combined with a method of tem-
perature control, such as Langevin dynamics, in order to simulate the NPT ensemble.
Such a barostat is a combination of the Nose-Hoover constant pressure method (295).
where an extra degree of freedom corresponding to a piston is added into the equations
of motions, and the piston fluctuation control is implemented by using a Langevin
dynamics as in (296).
The complete set of equations of motion used by NAMD when both the barostat
and the thermostat are enabled then are:
r′ =
p
m
+ βr
p′ = F − βp+ gp+ η
V = 3V ′β
β′ =
3V
W
(P − P0)− gβ + η
W
W = 3Nτ2kT
〈η2〉 = 2mgkT
h
τ = oscillationperiod
〈η2 〉 =
2WgkT
h
(3.19)
where β is the friction coefficient (thermostat degree of freedom), W is the mass
of piston, τ is the barostat time constant, η is noise on atoms, and η is the noise on
the piston. The piston represents an additional degree of freedom, which undergoes a
Langevin like dynamics, in analogy with the motion of each particle.
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3.2.8 Free energy calculations.
There are problems in biophysics for which a straightforward MD simulation can usually
not provide solutions due to the limitation in the length of the trajectories accumu-
lated. For example, a system could remain localized in a certain region during the
entire MD simulation because the free energy barriers to overcome are too high and
the Boltzmann probability that the system in a certain time can have sufficient energy
for that is simply too small that also a single event is not observed in the time of the
simulation. Another example is the case of protein folding where the folding time of
the most of the proteins is of the order of seconds, while direct simulation of these
systems can access the microseconds time scale at most. For this reason, the problem
of the correct sampling is of great importance and several free energy methods have
been developed to efficiently sample events that involve the passage through high free
energy barriers.
These free energy methods can be divided into:
i) methods aimed at reconstructing the probability distribution or the free energy
as a function of one or more coordinates. Examples are thermodynamic integration
(297, 298), where the free energy difference between a certain reference state and the
state of interest is measured by changing infinitely slowly the thermodynamic param-
eters characterizing the system so that at each stage along the path the system is in
equilibrium; umbrella sampling (299) which applies an artificial biasing potential to en-
hance sampling of unfavorable regions along a reaction coordinate; parallel tempering,
where elevated different temperatures are used to overcome barriers on several replicas
of the system that are simulated simultaneously;
ii) methods directly aimed at accelerating rare events and constructing reactive trajec-
tories, such as steered MD (300) based on the addition of external forces which reduce
the energy barriers (301).
The metadynamics method (302) provides in many cases a unified framework for com-
puting free energies and for accelerating rare events (303, 304, 305, 306). This approach
consists in a continuous addition of an history-dependent potential energy to the en-
ergy potential of the system, that forces the dynamics to explore previously not visited
conformations. Metadynamics requires the preliminary identification of a set of collec-
tive variables (CVs) that are functions of those atomic coordinates that describe the
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activated process of interest.
The forces acting on each atom are therefore corrected by the addition of a history-
dependent external contribution, and this correction can be simply obtained as the
derivative of the history-dependent potential energy Vt, with respect to the atom co-
ordinate. Vt is constructed as the sum of a set of Gaussian functions centered along
the trajectory
V (s, t) =
∑
t′<t
wexp
(
− s− s
2
t′
2δ2
)
(3.20)
where s is some CV, st is the value of s along the trajectory at at time t and the
sum run over all the times before t when a Gaussian deposition has been performed.
In this way, the system is discouraged from revisiting configurations that have already
been sampled.
After exploring all conformations defined within the CVs space, the free energy profile
does not change anymore and can be easily reconstructed as the opposite of the sum
of all Gaussians.
One of the more widely used versions of metadynamics is commonly referred to as
”well-tempered” metadynamics (307). In this approach, the sampling of the CVs is
performed at the enhanced temperature T+∆T and the local strength of the Gaussian
functions that are used to bias the sampling are reduced by an automatic rescaling.
This is achieved by using a different expression for the bias potential:
V (s, t) = kB∆T ln
(
1 +
W
τ
N(s, t)
kB∆T
)
(3.21)
where N(s,t) is the histogram of the s variables collected during the simulation,
∆T an input parameter with the dimension of a temperature, W an input parameter
with the dimension of an energy, and τ the Gaussian deposition rate. This guarantees
that the bias potential converges in a single simulation in the time limit, and does not
oscillate around the free energy profile solution. Indeed, as the bias deposition rate
decreases as 1/t, the dynamics of all the microscopic variables becomes progressively
closer to the thermodynamic equilibrium as the simulation proceeds (309).
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4Design of Human Granzyme B
Variants resistant to Serpin B9.
Human Granzyme B (hGB) is a serine protease involved in immune-mediated apop-
tosis. Its cytotoxicity makes it potentially applicable in cancer therapy. However,
the effectiveness of hGB can be hampered by the cytosolic expression of a nat-
ural protein inhibitor, human Serpin B9 (hSB9). Here we used computational
approaches to identify hGB mutations that can affect its binding to hSB9 with-
out significantly decreasing its catalytic efficiency. Alanine-scanning calculations
allowed us to identify residues of hGB important for the interaction with hSB9.
Some variants were selected, and molecular dynamics simulations on the mutated
hGB in complex with hSB9 in aqueous solution were carried out by Prof. Barth’s
group (RWTH Aachen) to investigate the effect of these variants on the stability
of the complex. The R28K, R201A and R201K mutants significantly destabilize
the interaction of the protein with hSB9. Consistently, all of these variants also
retained their activity in presence of the Serpin B9 inhibitor in subsequent in vitro
assays of wild-type and mutated hGB. In particular, the activity of R201K hGB
with and without Serpin B9 is very similar to that of the wild-type protein. Hence,
R201K hGB emerges as a promising species for anti-tumoral therapy applications.
4.1 Introduction.
Several strategies for anticancer therapy are based on human serine protease Granzyme
B (hGB) (31). hGB is the most important and well-studied member of the granzyme
family, secreted during the defence against virally infected and malignant cells. Each
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member exhibits unique expression patterns and substrate specificities (57). hGB man-
ages to kill tumor cell lines that are otherwise resistant against many cytotoxic drugs.
Its apoptotic activity is based on the proteolytic cleavage of several downstream cas-
pases and caspase substrates as well as caspase-independent proteins like Bid (310, 311).
This leads to cytochrome c release and mitochondrial permeability (60, 312, 313, 314).
These processes are crucial for apoptosis of, e.g., tumor cells (315, 316).
hGB-based therapeutic applications, being based on an endogenous protein of human
origin, have the great advantage of avoiding neutralizing antibody formation. This
prevents patient retreatment, as reported for constructs derived from various plant and
bacterial components (53). However, they are associated with a few drawbacks as well
(56, 317). One of the most severe of them is the inhibition of hGBs enzymatic activity
by human Serpin B9 (hSB9) (68, 72, 73, 318). Indeed, the hGB·hSB9 complex has prac-
tically zero catalytic activity (69, 72). At the molecular level, hSB9 inhibits hGB by
forming a reversible Michaelis complex, followed by a 1:1 covalent complex (319, 320):
a covalent bond is formed between the side chain oxygen atom of hGBs S183 (italics
are used to indicate hGB residues) and the carbonyl carbon of hSB9’s P1 residue (321).
Identifying hGB variants able to bind more weakly with hSB9 and thus retaining
(at least in part) protease activity may therefore dramatically increase the potential of
hGB for antitumoral applications. In order to rationally design such mutants, investi-
gators would benefit greatly from experimental structural information on the full-length
hGB·hSB9 noncovalent or covalent complexes. Unfortunately, such information is cur-
rently lacking.
Here we have addressed this issue by predicting the structure of the hGB·hSB9’s
Michaelis complex and by testing the predictions accuracy by measuring in vitro the
enzymatic activity of the wt hGB protein and its mutants in the presence of hSB9. Our
calculations were based on the structurally similar rat trypsin·M. sexta serpin complex
(319) and hGB (67) X-ray structures. We then identified key interactions at the inter-
face of the two proteins using the Robetta (28, 264) webserver, based on our structural
prediction.
Among the wild-type (wt) hGB residues involved in such interactions, we selected
residues which were not located in hGB’s active site. These are expected not to af-
fect hGB’s catalytic activity. Next, we designed several mutants (including R28K
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hGB·hSB9, R201A hGB·hSB9 and R201K hGB·hSB9) that could decrease the affinity
of the complex using computational alanine scanning mutagenesis (CASM).
CASM is a convenient and computationally fast strategy to investigate the determinants
of protein complex interactions (322), although it provides very approximate results.
In particular, CASM does not include hydration at the protein/protein interface (264)
in spite of the fact that water molecules may play a very important role for complex
stability. Furthermore, CASM does not allow to investigate the impact of mutations
(other than alanine) on the structural determinants. Finally, CASM does not allow
to take into account fully the flexibility properties of the complex. Therefore, we de-
cided to perform molecular dynamics (MD) simulations of wt and mutated hGB·hSB9
complexes in water solution, which allow us to successfully overcome the limitations of
the CASM approach albeit at the price of a greater computational cost. Free energy
calculations, which could provide quantitatively changes of the mutants relatively to
that of the wild-type, are computationally more expensive and provide quantities which
can only be related indirectly to enzymatic catalysis.
Those calculations allowed us to suggest that the three mutants above are destabilized
to the greatest extent among the mutants investigated here. On the other hand, the
others turned out to be almost as stable as the wt hGB·hSB9 complex. Consistently,
the measured enzymatic activity of the three mutants above was similar to that of wt
hGB. These mutants might be therefore promising for exploitation in therapeutic ap-
plications, depending upon further assessment of a putative intrinsic immunogenicity
due to the mutation itself.
4.2 Methods.
Molecular Modeling. We predicted the structure of human hGB·hSB9 complex by ho-
mology modeling based on the rat trypsin·M. sexta serpin B1 complex X-ray structure
(PDB ID: 1K9O) (319). These are suitable templates for hGB and hSB9. The sequence
identity (SI) between rat trypsin and hGB is 36%. The two proteins have similar length
(Fig. 4.1a), and they are functionally and structurally related (310, 323, 324). We thus
fitted the backbone of hGB structure with that of rat trypsin in complex with M. sexta
serpin B1 (Fig. A.1 in Appendix).
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Figure 4.1: Sequence alignments. Sequence alignments between rat trypsin and
hGB (a) and of M. sexta Serpin B1 and hSB9 (b), as obtained by using ClustalW
(http://www.ebi.ac.uk/clustalw). The hSB9’s active site residues are inserted in the yellow
box.
Two X-ray structures of hGB are available. These are the unbound form (66) (PDB
ID: 1FQ3) solved at a resolution of 3.6 A˚, and the form bound to a 5-residues peptide
(67), (PDB ID 1IAU) solved at 2 A˚ resolution. The latter is considered in this work.
The SI between M. sexta serpin B1 and hSB9 is 27% (Fig. 4.1b). Furthermore, serpin
B1’s active site is strongly conserved across the serpin family (325), including SB9 (Fig.
4.1b). Because the structure of hSB9 has not yet been solved, we built its structure
using homology modeling based upon the X-ray structure of the rat trypsin·M.sexta
serpin B1 complex (Fig. A.1 in Appendix), using MODELLERv7 software (221). The
top-scoring structure was identified based upon its stereochemical quality, checked us-
ing the PROCHECK software (326) as well as its DOPE (Discrete Optimized Protein
Energy) score (327), a statistical potential optimized for model assessment implemented
in the MODELLER software. The final RMSD between hSB9 and Serpin B1 and that
between human hGB and rat trypsin were both 0.7 A˚.
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The complex was inserted in a water box of edges 108×81×119 A˚3 including∼29,000
water molecules and 7 Cl- counterions. Periodic boundary conditions were applied. It
first underwent 5000 steps minimization and then 30 ns of molecular dynamics (MD)
at 300 K. The AMBER ff99SB (285), TIP3P (256) and Aaqvist (328) force fields were
used for the protein, water and counterions, respectively. The timestep was 2 fs. The
SHAKE algorithm (329) was applied to all chemical bonds. The particle mesh Ewald
method was applied to evaluate the long-range electrostatic interactions (330). Con-
stant temperature and pressure were achieved by coupling the system with a Langevin
thermostat (294) and a Nose-Hoover-Langevin barostat (296).
In the last few years, a number of methods have been developed for the identifi-
cation of hot spots in protein-protein interactions. They are represented on the one
hand by rigorous treatments based on physical effective energy functions such as free
energy perturbation. Because these methods that require a sufficient statistical sam-
pling, they are often extremely time and computationally consuming (331, 332). On
the other hand, these methods may be based on empirical treatments. These include
Molecular Mechanics/Poisson-Boltzmann surface area (MM-PBSA) approaches (333),
which use a simplified continuum solvent method. Computational alanine scanning
coupled with MD simulations, used here, might represent a good compromise between
speed and accuracy.
Mutants putatively destabilizing the complex and not affecting the active site struc-
tures were therefore identified using Baker’s alanine scanning procedure (28, 264).
Residues predicted to significantly (≥ 1 kcal/mol) decrease the binding free energy
upon mutation to alanine, thus destabilizing the interface, are defined as hot spots.
K27 hGB, R28 hGB and R201 hGB hotspots were identified here (Table A.1, Fig
A.1 in Appendix). Putative variants affecting the interactions between hSB9 and the
hotspots were built using the SWISS PDB Viewer software (222). These are: K27A
hGB·hSB9, R28A hGB·hSB9, R201A hGB·hSB9, R28E hGB·hSB9, R28K hGB·hSB9,
R201E hGB·hSB9, and R201K hGB·hSB9, as well as the double mutant R28A-R201A
hGB·hSB9. No clashes were present in the predicted structures.
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These variants were inserted in water boxes and counterions were added, similarly
to what was done for wild-type (wt) hGB·hSB9 (Table A.2 in Appendix). 50 ns MD
simulations were carried out for the variants as for wt hGB·hSB9. A cluster analysis
(334) was performed to identify representative structures of the conformational ensem-
ble of the wt hGB·hSB9 complex and to identify the variants which were stable during
the dynamics: R28A hGB·hSB9, R201E hGB·hSB9 and K27A hGB·hSB9 (see Results
Section). One single representative from each of those ensembles covered from 52% to
83% of the conformational space simulated. Thus, some of the structural properties
presented here are calculated for that representative. The NAMD 2.7 package was used
for all MD simulations (279).
Experimental methods. The cloning of the plasmid encoding the sequence of the hGB
fusion protein as well as the expression in HEK293T cells has been described before
(79). The transfection was done with 1 µg DNA according to the manufacturer’s using
RotiFect (Roth). The protein was secreted into the supernatant (335) and purified via
Immobilized Metal-ion Affinity Chromatography (IMAC). The cleared supernatant was
supplemented with 10 mM imidazole and loaded to an XK16/20 column (Amersham
/ GE Healthcare) containing 8 ml Sepharose 6 Fast Flow resin (Clontech / Takara).
The incubation, washing and elution buffers used, were as described previously (335).
The eluted protein was re-buffered into 20 mM Tris, pH 7.4, 50 mM NaCl, concen-
trated, aliquoted and stored at -80C. For the generation of an active protein with a free
N-terminus (63, 336), Enterokinase was added to the protein (0.02 U/µg with 2 mM
CaCl2 for 16 h incubation at 23 ◦C prior to use. The protein concentration was calcu-
lated after SDS-PAGE analysis and Coomassie staining using AIDA Image Analyzer
Software (Raytest Isotopenmessgera¨te).
For the expression of recombinant hSB9 the E.coli expression strain BL21 (DE3) was
used during a 4 L fermentation in synthetic medium. The bacteria were harvested 24 h
after induction with Isopropyl Thiogalactoside (IPTG). After centrifugation the bacte-
rial pellet was re-suspended in lysis buffer (50 mM NaH2PO4 , pH 8.0, 500 mM NaCl,
0.5 mM DTT) and sonicated six times for 60 s, 70%, 9 cycles. The supernatant was
supplemented with 10 mM imidazol and was purified via IMAC as described above.
After a second IMAC, the protein was re-buffered into 20 mM Tris, pH 7.4, 1 mM DTT
and further purified via anion exchange chromatography (Q-Sepharose XL, 1 ml, GE
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Healthcare) with a salt gradient of 0.05 - 1 M NaCl. For higher purity, size exclusion
chromatography (SEC) was done as the last step, using a Superdex 75 (GE Healthcare)
column in 20 mM Tris, pH 7.5, 50 mM NaCl, 1 mM DTT.
The complex formation between recombinant hSB9 and the hGB has been described
before (68, 72). 600 ng wild-type or mutated hGB fusion protein were incubated with
or without hSB9 (3-fold excess) for 1 hour at 37 ◦C under reducing conditions in 20 mM
Tris, pH 7.4, 50 mM NaCl and 1 mM DTT. The remaining activity was detected by
cleavage of 200 µM substrate Ac-IETD-pNA (Calbiochem/Merck) imitating the cleav-
age site of Pro-caspase 3. The reaction was monitored in a microplate reader in triplets
at 37 ◦C with an absorbance of 405 nm. The velocity of the activity was calculated
from the linear slope of the reaction during the first 10 minutes.
4.3 Results and discussion
We discuss here the structural features of wild-type (wt) and mutants of hGB in com-
plex with hSB9 in water solution, as obtained by 50 ns of MD in explicit solvent.
wt hGB·hSB9 complex. The Root Mean Square Displacement of the wt complex
with respect to the initial structure (RMSD hereafter) fluctuates along the MD trajec-
tory around 3.2 ± 0.2 A˚ for the last 20 ns of the MD run (Table 4.1, Fig. 4.2). This
suggests that the structure is equilibrated after 30 ns. The following analysis is per-
formed therefore for the last 20 ns. The distance between hGB’s and SB9’s centers of
mass (DCOM hereafter) is 49 ± 0.4 A˚, and the solvent-accessible surface area (SASA)
(337) is 29,680 ± 371 A˚2 (Table 4.1, Fig. 4.2). The protein-protein contact surface as
obtained by cluster analysis (see Method section) involves 4 salt bridges, 2 hydrogen
bonds and 3 hydrophobic contacts (Table 4.2, Fig. 4.3). They are significantly different
from those of the template (Table 4.2, Table A.3 in Appendix, Fig. 4.3).
Design of mutated wt hGB·hSB9 complexes. We identified mutations that
might affect the stability of the complex, without altering hGB enzymatic activity.
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Complex RMSD(A˚) DCOM(A˚) SASA(A˚2)
wt hSB·hSB9 3.2 ± 0.2 3.4 48.9 ± 0.4 49.1 29680.5 ± 371.0 29736.7
R28A hSB·hSB9 3.6 ± 0.3 3.6 49.4 ± 0.5 50.3 29715.1 ± 296.1 29789.3
R28E hSB·hSB9 5.5 ± 0.5 4.9 49.6 ± 0.6 49.2 30156.7 ± 298.3 29713.1
R28K hSB·hSB9 = 4.9 = 52.6 = 30395.8
R201A hSB·hSB9 = 3.9 = 47.0 = 31053.1
R201E hSB·hSB9 2.7 ± 0.1 2.6 49.3 ± 0.2 49.7 29395.5 ± 251.6 29505.0
R201K hSB·hSB9 = 3.4 = 49.1 = 29736.7
R28A-R201A hSB·hSB9 5.7 ± 0.6 6.8 48.5 ± 1.0 50.1 30071.6 ± 355.6 29874.5
K27A hSB·hSB9 3.1 ± 0.2 3.5 50.2 ± 0.3 50.3 30333.7 ± 222.2 30412.6
Table 4.1: Structural Properties of wt and mutated complexes. Values of RMSD,
of DCOM and of SASA as obtained by averaging the MD trajectories (left columns) and
in the final MD snapshots (right columns). The averages are not taken for the R28K
hSB·hSB9, R201A hSB·hSB9 and R201K hSB·hSB9, which are unstable during the dy-
namics.
Figure 4.2: Structural properties. Structural properties. RMSD, DCOM and SASA
(See text for a definition of these quantities) for wt and mutated hGB·hSB9 complexes,
plotted as a function of simulated time.
For this purpose, we first used Baker’s computational alanine scanning mutagene-
sis (CASM) procedure (28, 264), followed by molecular dynamics (MD) simulations.
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Complex Salt bridges Hydrogen bonds Hydrophobic contacts
wt hSB·hSB9 K27 -E340 Q23 -D258 L26 -M343
R28 -E344 N202 -S334 P82 -A339
K135 -E266 F85 -A339
K180 -E201
R28A hSB·hSB9 K27 -E340 Y17 -M343 L157 -V337
K135 -E266 R201 -V337 A28 -M343
K180 -E201 N202 -S334
R28E hSB·hSB9 K83 -E340 R201 -C335 L157 -V337
K180 -E201 N202 -E201 F85 -V338
R201E hSB·hSB9 K24 -D258 R28 -M343 P82 -A339
K180 -E201 F85 -V338
K135 -E266 L26 -M260
R28A-R201A hSB·hSB9 K24 -D258 S25 -S262 A28 -M343
L26 -S262 A201 -V337
P132 -S334 F85 -V338
N202 -S334
K27A hSB·hSB9 K135 -E264 G134 -E201
K135 -E266
R28 -E344
Table 4.2: Contacts between hGB and hSB9. The Table reports salt bridges,
hydrogen bonds and hydrophobic interactions in wt and R28A, R28E, R201E, R28A-
R201A and K27A hGB·hSB9 complexes.
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Figure 4.3: Protein-protein interfaces. Interfaces between hGB (grey) and hSB9
(blue) in the wt and mutated R28A, R28E, R201E, R28A-R201A and K27A hGB·hSB9
complexes which turned out to be stable in our MD simulations. Residues forming salt
bridges (yellow sticks), hydrogen bonds (orange sticks) and hydrophobic interactions (red
spheres) are highlighted.
CASM provides a rough estimate of the changes in the interaction free energy (DDG)
between the two proteins upon mutation of hGB interface residues to Ala. The largest
DDG values turned out to be associated with the K27A hGB·hSB9, R28A hGB·hSB9
and R201A hGB·hSB9 (Table A.1 in Appendix). Next, we performed 50 ns MD
simulations of the mutations with the largest DDG along with others involving the
same positions (R28A-R201A hGB·hSB9, R28E hGB·hSB9, R28K hGB·hSB9, R201E
hGB·hSB9 and R201K hGB·hSB9) (Fig. A.3) in Appendix) in explicit solvent.
In R28A hGB·hSB9, the RMSD, DCOM and SASA are slightly larger than those
of wt hGB·SB9 (Table 4.1, Fig. 4.2). The K27 -E340, K135 -E266 and K180 -E201 salt
bridges, present in wt hGB· hSB9, are formed as well in this case. The R28A-E344
salt bridge is lost (Table 4.2). The N202 -S334 H-bond is maintained, while the Q23 -
D258 H-bond is lost. Y17, which does not form H-bonds in wt, in this case H-bonds
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to M345. The L26 -M343, P82 -A339 and F85 -A339 hydrophobic contacts, present in
the wt, are absent here. However, M343 in this case forms a hydrophobic contact with
A28. A new contact L157 -V337 is formed as well (Table 4.2, Fig. 4.3). This complex
therefore appears to be relatively stable during the time-scale simulated, although some
of the interactions present in wt hGB·hSB9 are lost and some other absent in the wt
hGB·hSB9 are formed.
In R28E hGB·hSB9, the RMSD, DCOM and SASA are larger than those of wt
hGB·hSB9 (Table 4.1, Fig. 4.2). The K135 -E266, K27 -E340 and R28 -E344 salt
bridges are lost but E340 forms a new salt bridge with K83. N202 form H-bonds
to E201 instead of H-bonding to S334 as in wt hGB·hSB9. R201 H-bonds to C335.
The Q23 -D258 salt bridge is also lost. F85 forms a hydrophobic contact with V338
instead of A339, as in wt hGB·hSB9. L157 forms a hydrophobic contact with V337
which is not present in wt hGB·hSB9 (Table 4.2). L26 does not interact with hSB9’s
interface (Table 4.2) unlike in the wt hGB·hSB9.
We conclude that in spite of the increased DCOM and SASA values, the formation of
new interactions stabilizes a rearranged hGB·hSB9 interface (Fig. 4.3). The complex
is definitively stable in the timescale investigated.
In R28K hGB·hSB9, the RMSD, DCOM and SASA increase monotonically during
the dynamics, pointing to a strong destabilization of the complex (Table 4.1, Fig. 4.2).
Several stabilizing interactions at the interface are already lost in the time-scale inves-
tigated (data not shown). This complex is definitively unstable.
In R201A hGB·hSB9, the RMSD, COM’s hGB·hSB9 distance and SASA increase
with simulated time (Table 4.1, Fig. 4.2). Also in this variant, several interface inter-
actions are lost at the end of the dynamics (data not shown). This complex is clearly
unstable.
In R201E hGB·hSB9, RMSD, DCOM and SASA are comparable to the ones of the
wt hGB·hSB9 complex (Table 4.1, Fig. 4.2). The K27 -E340 and R28 -E344 salt bridges
are lost, but the K180 -E201 and K135 -E266 bridges are preserved and K24 -D258 is
newly formed (Table 4.2). R28 forms a new H-bond with M343. This compensates
for the loss of the N202 -S334 bridge. The hydrophobic contacts are the same as in wt
hGB·hSB9 (Table 4.2). The complex remains stable (Fig. 4.3).
In R201K hGB·hSB9, the RMSD, COM’s hGB-SB9 distances and SASA increase
monotonically during the entire dynamics (Table 4.1, Fig. 4.2). Several stabilizing
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interactions at the interface are lost at the end of the MD (data not shown). In this
case, the complex is unstable.
In R28A-R201A hGB·hSB9, the RMSD is 5.7 ± 0.6 A˚. This relatively large value
is caused by a series of conformational rearrangements (Fig. 4.3). However, these rear-
rangements are associated with the formation of a significant number of protein-protein
contacts. S262 H-bonds to S25 and L26. S334 H-bonds to the side chain of N202 and
the carbonyl of P132 P132 backbone. A28 and A201 form hydrophobic contacts with
M343 and V337, respectively. F85 interacts with V338. Although protein/protein con-
tacts involving K27, R28A, K135 and K180 are lost, K24 forms an alternative salt
bridge with D258. Consistently, DCOM and SASA do not vary largely (Table 4.1, Fig.
4.2). We conclude that this complex is rather stable. Indeed, the significant rearrange-
ments observed are associated with new interactions at the interface (Table 4.2).
n K27A hGB·hSB9, the RMSD is similar to that of wt hGB·hSB9. The DCOM
distance and the SASA fluctuate around a larger value than that of wt hGB·hSB9
(Table 4.1, Fig. 4.2). The salt bridges involving residue 27 and K180 are obviously
lost, while the ones at R28 and K135 are retained. However, a new hydrogen bond
(between G134 and E201) is formed. No hydrophobic interactions are present, in con-
trast to wt hGB·hSB9 (Table 4.2). However, despite the loss of interface contacts, the
complex remains stable (Table 4.1, Fig. 4.3). Indeed, DCOM and SASA values do not
significantly increase with time (Fig. 4.2).
Comparison with previous studies. The interface between hGB and full-
length hSB9 in our model shows significant differences from an earlier structural pre-
diction of hGB in complex with 12 residues (334-345) belonging to hSB9’s reactive
center loop. The latter is a solvent exposed stretch of amino acids representing the
primary site of interaction with hGB (338). The differences are as follows: (i) in our
complex, E201, D258 and E266 interact with residues of SB9 other than those of the
loop modeled by (338); and (ii) our model features the K27 -E340 and R28 -E344 salt
bridge, while in (338), the model features the K27 -E344 salt bridge. R28 and K180
form salt bridges in our model (Table 4.2), while they form H-bonds in Sun et al’s
model (338). This suggests that inclusion of the entire hSB9 may be important to
describe the interface.
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Assays on enzymatic activity mutants in vitro. Taken together, the in sil-
ico results point to a few mutants featuring the largest destabilization in terms of
loss of contacts as well as an increase in DCOM distance, SASA and RMSD: R201A
hGB·hSB9, R201K hGB·hSB9 and R28K hGB·hSB9. In these mutants, the enzymatic
activity of hGB (63) may not be too dissimilar from wt hGB activity because the ac-
tive site is likely to exhibit the same structure of wt hGB. The relatively low predicted
affinity of SB9 for hGB suggests that the activity of mutated hGB·hSB9 complexes will
still be significant.
The other mutant complexes exhibit similar interacting surface (see DCOM and SASA
values in Table 4.1 as well as a similar network of specific contacts at the interface
(Table 4.2). In this case, enzymatic activity is predicted to be affected by hSB9 bind-
ing in a manner not too dissimilar from the behaviour of wt hGB·hSB9 (Fig. A.3 in
Appendix).
However, it should be kept in mind that no quantitative activity predictions of en-
zymatic activity can be derived from classical molecular dynamics simulations and
structural observations.
All proposed mutations were introduced into a hGB fusion protein by site-directed mu-
tagenesis such that only single amino acids were exchanged. During the expression it
was shown that all variants could be stably expressed in HEK293T cells and purified
yielding the same amount of protein as wt hGB (data not shown).
We next measured the activity of wt and mutated hGB in absence and presence of
recombinant hSB9. Enzymatic activity was detected by cleavage of the peptide Ac-
IETD-ppNA, which mimics the cleavage site of the hGB substrate Pro-caspase 3 (63).
We find that R201A hGB·hSB9, R201K hGB·hSB9 and R28K hGB·hSB9 in absence
of hSB9 feature catalytic activity similar to that of WT hGB (Fig. 4.4). Enzymatic
activity is significant also in the presence of hSB9, ranging from 46% R201A to 94%
R201K. Our predictions are consistent with these results. The catalytic activity of the
other mutated hGB·hSB9 complexes decreases relative to wt hGB, and is even lower
in the case of the double mutant. Their remaining enzymatic activity after complexing
ranges from 0.5% for the double mutant R28A-R201A to 25% for R28E. An exception
is R28A, with a remaining activity of 54% in contrast to computational predictions
(Fig. 4.4).
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Figure 4.4: In vitro assays. Activity of hGB wt and mutant isoforms in presence
(green histograms) or absence (grey histograms) of hSB9. The activity of the K27A hGB
mutation without hSB9 was already measured by Sun et al (72).
In conclusion, only R28K hGB, R201A hGB, R201K hGB keep their enzymatic
activity even in the presence of hSB9. Our predictions are fairly consistent with these
experimental findings.
4.4 Concluding remarks.
We have presented a combined in silico and in vitro study aimed at designing mutants
of hGB which retain their catalytic activity even in the presence of hSB9. The exper-
imental data correlate fairly well with the computational predictions. In particular,
R28K hGB, R201A hGB, R201K hGB did not lose their enzymatic activity and still
retain most of it after incubation with the inhibitor hSB9. The mutant of choice for
future therapeutic application is R201K hGB because, in the presence of hSB9, it pre-
serves a comparable activity with wt hGB in the absence of the inhibitor (Fig. 4.4).
Further in vivo studies with this candidate are required to test its activity in the cell,
as well as potential immunogenicity and unspecific toxicity.
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5Investigation of PARP10-GSK3β
interactions at the molecular
level
5.1 Introduction
Carcinogenesis is a multistep process involving the progressive accumulation of genetic
and epigenetic alterations that ultimately transform normal cells into neoplastic cells.
The hallmarks of most of the cancers have been set in the discovery of mutations that
produce oncogenes with dominant gain of function, such as Ras and c-MYC, involved in
mitogenic cell signaling leading to increased cellular proliferation, and tumor suppres-
sor genes with recessive loss of function, such as DNA repair factors and p53, mainly
involved in the maintenance of genomic stability and cell cycle regulation (339, 340).
In recent years, several promising drug targets have been identified and novel drugs
synthesized that target specific DNA repair proteins (341). These agents have shown
impressive anti-cancer effects in preclinical studies in combination with classical cyto-
toxic treatments such as chemo- or radiotherapy.
Unfortunately, the efficacy of these is often impaired from the DNA repair mecha-
nisms themselves (342, 343). One of the most advanced classes of DNA repair inhibitors
is represented by inhibitors of poly-ADP-ribosylation (340). Poly-ADP-ribosylation is a
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post-translational modification that occurs immediately after exposure of cells to DNA
damaging agents. Poly-ADP-ribose polymerases (PARPs) catalyze the formation of a
complex branched ADP-ribose polymer using NAD+ as a donor of ADP-ribose residues
(130). PARPs can covalently modify themselves (automodication) or other proteins
(heteromodication). In humans, 17 genes and proteins have been identified, which are
characterized by a conserved PARP signature motif. This motif is represented by the
highly conserved amino acid sequence ”HYE” that forms the active site (344). How-
ever, some of them seem to be catalytically inactive or possess mono-ADP-ribosylation
rather than poly-ADP-ribosylation activity (87, 345). Thus, the PARP family is also
referred to as diphtheria toxin-like ADP-ribosyltransferases (ARTDs) family (97, 346).
PARP10 is a peculiar member of the family in that it features only mono-ADP-
ribosylation activity (34). It is localized in the nucleus and the cytoplasm. PARP10
was shown to act as a mono-ADP-ribosyltransferase that automodifies glutamate 882.
Intriguingly, the glutamate of catalytic ”HYE” triad, conserved across all the other
PARP enzymes, is here missing. It is replaced by the isoleucine 987 (34) (Fig. 5.1a)
Figure 5.1: Superposition of PARP1 and PARP10 catalytic sites. Superposition
of PARP1 and PARP10 catalytic sites, as shown by the X-ray structrures of the two
proteins (347) (Karlberg et al., paper unpublished). In PARP10, the Glu988 is missing
and is structurally replaced by the Ile987. From (34).
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Hence, the catalytic mechanisms of PARP10 is different from those of the other
PARP enzymes. The acidic target residue of the protein substrate has been proposed
to substitute functionally the catalytic glutamate. This could be achieved by using
substrate-assisted catalysis to transfer ADP-ribose (34).
In order to understand how PARP10 is regulated and in which physiological pro-
cesses it is involved, it is crucial to point out which molecules PARP10 can modify and
where the modification site is located.
Until now, PARP10 is only known to functionally associate with core histones and
c-MYC (99). Thus, a protein microarray analysis was carried out to characterize new
PARP10 interactors. 78 novel potential PARP10 substrates were identified with differ-
ent functions (Fig. 5.2). 11 of them were validated with independent experiments and
using different protein sources (Table 5.1).
Figure 5.2: Identified PARP10 substrates.
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Protein Function
PDGFB Growth factor
GSK3β Kinase
IKK Kinase
KCNAB1 Voltage-gated channel
ACVR1 Serine/threonine kinase receptor
FES Kinase
SRPK2 Kinase
CDK5 Kinase
p-TEFb Kinase
DYRK1 Kinase
YY1 Transcription factor
Table 5.1: Validated PARP10 substrates. Validated PARP10 substrates identified
with protein microarray experiments (internal communication, unpublished).
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Pharmaceutically relevant is the fact that PARP-dependent ADP-ribosylation in-
hibits GSK3β serine-threonine kinase activity (Table 5.1) (109).1 Indeed, the thera-
peutic potential of GSK3β inhibitors has become an important area of investigation in
cancer chemotherapy (348). Moreover, GSK3β-mediated signaling has been shown to
be involved in neuronal development (349), bipolar disorder (350), Alzheimer’s (351)
and Parkinson’s disease (352).
Here, I have used computational methods to investigate GSK3β-PARP10 interac-
tions at the molecular level, so far lacking. To guide the molecular docking, we have
made the plausible (but as yet not demonstrated) assumption that one of GSK3β’s
Glu or Asp may functionally replace the missing equivalent in PARP10 of Glu988 of
PARP1. Because experimental evidence (35, 36, 353) show that also positively charged
residues from cellular partners play a crucial role in the catalysis, GSK3β’s exposed
Arg and Lys residues were also considered and included in the computational setup
(see next section).
Previous preliminary experiments in Prof. Lu¨scher’s lab ruled out Glu53, Glu121 and
Glu279 from the pool of 76 possible candidates (354). On the basis of our calculations,
additional 6 residues (Asp77, Glu211, Asp264, Glu290, Arg96, Lys197) were selected.
Experiments carried out in Prof. Lu¨scher’s lab were then performed to validate or
disprove my predictions.
5.2 Computational methods.
5.2.1 Available structural information for the isolated moieties.
The GSK3β structure alone or in complex with diverse inhibitors have been solved by
X-ray crystallography (355, 356). Here we consider the structure of the protein alone
taken from PDB ID 1H8F (354).
The PARP10 double mutant structure in complex with the inhibitor 3-aminobenzamide
(PDB ID 3HKV) (Karlberg et al., unpublished) is deposited in the Protein Data Bank
1The protein belongs to the glycogen synthase kinase subfamily. It is involved in many intracellular
signaling systems. It functions in diverse cellular processes including proliferation, differentiation,
motility and survival. Since its downstream targets include several key transcription factors such as
c-MYC, it is regarded as an important modulator of cell physiology, including proliferation and death
(33).
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(PDB) (217). The PARP10 structure in complex with the NAD+ cofactor has not
yet been solved. However, recent computational studies (357) highlighted the presence
of a common, scorpion-shaped structural motif recognizing the NAD+ substrate. In
particular, structural similarity has been found, despite the sequence diversity, between
the NAD+-binding motif of the bacterial diphtheria toxins and the structurally known
ARTDs. 8 structures complexed with NAD+ have been reported, with slightly different
NAD+ conformations (Fig. 5.3). The NAD+ nicotinamide moiety shows conserved
interactions with the scorpion motif and the adenine moiety a small conformational
variability (357).
Figure 5.3: PARP10 scorpion motif. The nicotinamide moiety in conserved position
is in the orange circle, the 8 NAD+ conformations from (357) in the blue box.
5.2.2 Docking NAD+ onto PARP10.
We predicted the structure of PARP10 in complex with NAD+ by protein-ligand dock-
ing, based on the published structure of PARP10 (PDB ID 3HKV) in complex with the
inhibitor 3-aminobenzamide (3AB). 3AB is an analog of the NAD+ nicotinamide moi-
ety and is located close to the catalytic residues H887 and Y919. In order to guide the
docking procedure, we introduced two set of information: i) the interactions (hydrogen
bonds and hydrophobic interactions) formed by 3AB in the PARP10 pocket, introduced
as unambiguous distance restraints; ii) the common structural features shared by other
poly-ADP-ribose polymerases and ADP-ribosylating toxins (357), described in the pre-
vious section. In particular, PARP10 catalytic residues His887 and Tyr919 and the
NAD+ were defined as active residues (see definition of active and passive residues in
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Chapter 3 of this thesis).
The protein-ligand docking was performed using the software HADDOCK (for a de-
scription of the method, see Chapter 3 of this thesis) (21). The best structure belonging
to the best cluster, in terms of HADDOCK scoring function (255) was retained. The
HADDOCK scoring function takes into account several parameters, i.e. the van der
Waals, electrostatics, restraint violation, desolvation and symmetry restraint energies
and the buried surface area (358).
5.2.3 Docking PARP10/NAD+ onto GSK3β.
The protein-protein docking between PARP10 and GSK3β was also performed using
the software HADDOCK (21).
We used the active site residues His887 and Tyr919 and the NAD+ as ’active residues’
(21) for PARP10 in all of the HADDOCK runs. Each run was characterized by a differ-
ent set of active residues for GSK3β. In particular, we used: i) all possible modification
sites (Glu, Asp, Arg, Lys) characterized by a solvent accessibility of more than 40%,
a requisite for the active residue to be enough exposed on the protein surface (21); ii)
all possible pairs formed by one negatively charged (Asp or Glu) and one positively
charged (Lys or Arg) residue, characterized by a structural distance ≤ 6 A˚. The latter
option was explored in order to take into account the possibility that the GSK3β cat-
alytic Asp or Glu could be assisted by Lys or Arg as active residues for GSK3β (35, 36).
A similar procedure as above was carried out to identify the best HADDOCK adduct.
That was indeed identified in terms of HADDOCK scoring function, after having re-
tained for each run the best structure belonging to the best cluster as in (359, 360).
5.2.4 Experimental methods (Carried out by M.Sc. Karla Fejis in the
lab of Prof. Lu¨scher at the Medical School of RWTH Aachen
University).
Site-directed mutagenesis. Primers were designed using Agilent Technologies’ -
QuickChange Primer Design tool and were ordered from Sigma. Phusion Polymerase
(New England Biolabs) was used for the PCR according to manufacturers instructions
with exception of the elongation time, which was increased to 1 minute per kb. 2 U
Dpn1 (Fermentas) was added to the PCR reaction mixture afterwards and incubated
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for at least one hour at 37◦ C, to digest all methylated, i.e. non-mutated DNA before
heat shock transformation. All constructs created thus were sequenced to ensure suc-
cessful mutagenesis without acquisition of any other mutations.
ADP-ribosylation assays. ADP-ribosylation assays were routinely carried out at
30C for 30 minutes unless indicated otherwise. The reaction mixture (50 mM Tris-HCl,
pH 8.0, 0.2 mM DTT, 5 mM MgCl2 and 50 µM β-NAD+ (Sigma) and 1 µCi [32P]-β-
NAD+ (Amersham Biosciences) was added to 1 µg enzyme in a total reaction volume
of 30 µl. Reactions were stopped by adding SDS sample buffer and were subsequently
boiled and run on SDS-PAGE. Incorporated radioactivity was analyzed by exposure of
the dried gel to X-ray film. Samples used in subsequent kinase assays were cooled on
ice before washing of beads with coupled GST-GSK3β in kinase assay buffer.
Kinase assays. Kinase buffer: 5 mM MOPS pH 7.2, 2.5 mM β-glycerophosphate, 1
mM EGTA, 0.4 mM EDTA, 4 mM MgCl2, 50 µM DTT and 40 ng/µl BSA. [32P]-γ-ATP
was diluted to 0.16 µCi/mul in 250 µM ATP in 3x kinase assay buffer. 25ng GST-
GSK3β or precipitated material was incubated in a reaction volume of 25 µl containing
5 µl 0.16 µCi/µl [32P]-ATP solution and 5 µg substrate peptide RRRPASVPPSP-
SLSRHS(pS)HQRR (Millipore), unless the substrate peptide was titrated in indicated
concentrations. After incubating at 30◦ C for 15 minutes the reaction was stopped
by placing on ice. Routinely 10 µl aliquots were spotted on P81 paper in duplicate,
washed with 0.5% phosphoric acid and air-dried before scintillation counting. SDS-
sample buffer was added to the samples analyzed by SDS-PAGE and subsequent au-
toradiography. Statistical significance was determined by employing two-sided student
t-tests.
5.3 Results.
5.3.1 Structural prediction PARP10-NAD+.
The best scoring structure derived from the ligand-protein procedure is represented in
Fig. 5.4.
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Figure 5.4: PARP10-NAD+ complex. PARP10 (purple cartoon) in complex with
NAD+ as resulting from the docking procedure. The PARP10 catalytic residues His887
and Tyr919 are shown in green sticks, the known NAD+ conformations (357) as blue lines.
In the docked NAD+ pose, the nicotinamide moiety preserves the main interactions
with the protein if compared (Fig. 5.4) with the other known NAD+ included in the X-
ray structures of the other proteins characterized by the same scorpion motif as PARP10
(357). These are: exotoxin A (361), diphteria toxin (362), ecto-ADP-ribosyltransferase
2.2 (363), cholera toxin (364), C3 exoenzyme (365), C3stau2 exoenzyme (366), VIP2
(367) and CDTa (368).
5.3.2 Docking PARP10-GSK3β.
Several plausible complex structures were predicted, in which a negatively charged
residue and/or a positively charged residue were close to the PARP10 binding site.
According to the docking results, the following residues were chosen for preliminary
experimental tests: Asp77, Lys197, Asp264 and Glu290, Arg96 and Glu211. Glu97 and
Lys205 were also considered, due to the structural proximity with Arg96 and Glu211,
respectively. The corresponding complexes arising from docking calculations are shown
in Fig. 5.5.
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Figure 5.5: Docking poses. Docking poses for Asp77, Arg96, Lys197, Glu211, Asp264,
Glu290, Arg96-Glu97 and Arg205-Glu211. GSK3β is represented in blue cartoons, PARP10
in red. NAD+ is represented in yellow sticks, the potential modification site in green.
Limitation of the model. A limitation of this prediction is given by the fact
that the mutations required to test the substrate could cause conformational changes.
In this respect, large-scale molecular dynamics simulations could be performed. The
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calculations may allow for structural rearrangements of the PARP10-GSK3β complex,
leading to a more accurate interaction pose that observed with the docking procedure.
5.3.3 Mutations.
The Asp77, Arg96, Lys197, Glu211, Asp264, Glu290 single mutants and the Arg96-
Glu97 and Arg205-Glu211 double mutants were expressed based on my predictions. If
those GSK3β residues would play a role for the PARP10 catalytic activity, then these
mutants should not be mono-ADP-ribosylated, thus retaining their kinase activity.
Then, Karla Fejis in the lab of Prof. Lu¨scher carried out kinase and ADP-ribosylation
in vitro assays on the GSK3β mutants (see Methods for details). It was found that
they still get mono-ADP-ribosylated.
5.4 Discussion.
My biocomputing allowed for identifying 6 putative charged residues playing a role for
PARP10/GSK3 interactions. None of them turned out to play a role for the binding
in vitro. However, the implications for in vivo conditions should be taken with great
care. Indeed:
i) different acceptor sites in different PARP enzymes have been reported in the litera-
ture (35, 36, 369). In particular:
• on PARP1 (35) and PARP2 (36) both glutamic acid and lysine residues are
automodified;
• the recently identified mono-ADP-ribosyltransferase PARP15 was shown to mod-
ify neither acid nor basic residues, but threonine or serine instead (369);
• other mono-ADP-ribosyltransferases have been shown to modify also cysteines
and arginines (353).
Although the substrate-assisted catalysis requires an acidic residue (aspartate or glu-
tamate), these alternative mechanisms cannot be excluded in the case of PARP10 and
thus, further investigations are required to clarify the nature of the GSK3β acceptor
residue(s).
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ii) glycation (370, 371) can modify lysines non-enzymatically, covering the modification
site;
iii) experimental issues, such as the lack of antibodies against mono-ADP-ribosylation
on specific residues and the lack of reliable mass spectrometry methods, as well as
computational issues, such as the difficulty to obtain reliable docking results in blind
calculations (i.e. without any experimental data related to the protein-protein inter-
face) (18, 372) make the identification of modification sites a real challenge. In this
context, a major drawback was represented by dealing with a protein (GSK3β) belong-
ing to the extremely conserved (373) family of protein kinases. Further experiments
would therefore greatly help identify a smaller interface region. This in turn would
increase the reliability of docking predictions (21).
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6Molecular simulation of the
NGF-TrkA complex.
6.1 Introduction
Neurotrophins are growth factors essential for the regulation of development, main-
tenance, and function of vertebrate nervous system (374) and for the modulation of
synaptic transmission (128). The growth factor family comprises nerve growth fac-
tor (NGF), the brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and
neurotrophin-4 (NT-4). NGF (121) is the founding member of the neurotrophins. Most
of the signaling processes in the synaptic compartment are activated by NGF and its
binding to the tropomyosin-related kinase A (TrkA) (37, 375) cognate receptor. NGF
is involved in several disease states. The derangement of signaling processes involving
NGF and TrkA is associated with the etiology of Alzheimer’s disease (38, 120, 376, 377).
NGF/TrkA have been proposed to interact with a variety of cellular partners, in-
cluding the low-affinity p75 receptor (378, 379) and the Abeta protein (376, 380). These
interactions might play a role for the progress of Alzheimer’s disease. Moreover, NGF-
mediated TrkA activation typically leads to the regulation of synaptic strength and
plasticity through a complex signaling pathway that involve several small G proteins,
including Ras, Rap-1, and the Cdc-42-Rac-Rho family, as well as pathways regulated by
MAP kinase, PI 3-kinase, phospholipase-C-gamma (PLC-), NFkB, and atypical protein
kinase C pathways (124, 381, 382).
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Binding of proteins to their protein targets is expected to occur via two different
molecular mechanisms (383, 384). In the ”induced fit” model (383), binding of a protein
to a ligand or another protein leads to a conformational change apt for optimal bind-
ing. In the ”conformational selection” mechanism (384), some of the conformational
states may have binding sites matching the shape and the chemistry of the interactor.
The binding of the latter stabilizes these states with a ”population shift” toward these
conformers (385, 386). Mechanisms involving both a conformational selection step and
an induced fit step have also been proposed (387, 388).
Here we use molecular simulations tools to investigate whether the conformational
mechanism plays a role for NGF-TrkA recognition of cellular partners.
This complex is a dimer and features a ”crab” shape with two extended pincers. Such
”crab” body, of C2-fold symmetry, is composed of the NGF homodimer flanked by the
two pincers, each consisting of the five domains (D1-D5) of TrkA (40) (Fig. 6.1).
Figure 6.1: NGF structure complexed with TrkA extracellular domains (two
side views). The TrkA extracellular domains are in orange and shown as ribbons with
transparent molecular surface, and NGF is blue/green and only shown as ribbons. Cell
membrane is depicted as a rectangular box. This picture has been taken from ref. (40).
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We investigate structure, conformational fluctuations and energetics associated with
the motion of the TrkA pincers in the structures by metadynamics (302) calculations.
These calculations allow the accurate reconstruction of the free energy landscape of a
biological system and the exploration of conformations separated by high free energy
barriers.
6.2 Methods.
6.2.1 Equilibration.
The TrkA-NGF crystal structure was taken from ref. (40) (PDB ID 2IFG). The sys-
tem underwent equilibration by classical MD, performed by using NAMD 2.7 (279).
The overall charge of the system was neutralized by adding 14 Na+ ions. The AM-
BER99SB (285) force field was used for the biomolecules and counter ions, and the
TIP3P (256) force field was used for water molecules. Asparagine glycosylation sites
(Asn95, Asn121, Asn188, Asn262, Asn281, Asn358) of Alpha-D-Mannose, Beta-D-
Mannose, 2-(Acetylamino)-2-Deoxy-α-D-Glucopyranose and N-acetyl-D-Glucosamine
were included in the simulations since deemed to stabilize the NGF/TrkA complex
(40) and treated within the CHARMM36-all atom force field (389). Electrostatic in-
teractions were calculated using the Particle Mesh Ewald method (390). The time-step
was set to 2 fs. The SHAKE algorithm (391) was applied to fix all bond lengths.
6.2.2 Free energy calculations.
The free energy is calculated in terms of specific CVs, which describe the large-scale
motions of TrkA’s pincers. To define such CVs, we identify the NGF as the fulcrum of
the pincer large scale motion. Next, we consider three regions of the pincers:
(i) the N-terminal regions (from Cys36 to Asn188, and from Cys36’ to Asn188’ (the
symbol ’ refers to the second pincer);
(ii) the central regions (from Ala189 to Glu339 and from Ala189’ to Glu389’);
(iii) the C-terminal regions (from Thr340 to Pro382 and from Thr340’ to Pro382’).
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The CVs form therefore a fan-shaped set of descriptors (Fig. 6.2), defined by the
three θ1, θ2, θ3 bending angles:
θi = a cos
(v1i · v2i)
(|v1i||v2i|) i = 1, 3 (6.1)
where v1i and v2i (i=1,3) are the three couples of vectors that connect the centers
of each above mentioned TrkA regions with the NGF center of mass, as shown in Fig.
6.2.
θi depends on the orientation of the aforementioned three couple of vectors (v1i and
v2i i=1,3) (Fig. 6.2). We consider as reference coordinates the X-ray structure of (40),
where the values of θ1, θ2, θ3 are 64◦, 105◦ and 153◦, respectively.
The free energy is calculated using 0.15 µs of well-tempered metadynamics within
the framework of PLUMED (392). Gaussians of 0.2 kcal/mol height were deposited at
one picosecond time interval, with a bias factor of 10. A temperature of 300 K was
enforced using a Langevin thermostat. Four walkers were added in order to accelerate
the free-energy convergence (393).
The free energy calculations were carried out by Dr. A. Pietropaolo (U. Catanzaro,
Italy).
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Figure 6.2: Collective variables (θ1, θ2, θ3) for the pincer movement of
NGF/TrkA complex (40). The collective variables are identified by the angles formed
by the two pincers, highlighted by the black, blue and red lines, whose arrows point to the
center of mass of each TrkA region.
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6.3 Results
6.3.1 Structural features.
The calculations point to the presence of three, almost isoenergetic free energy valleys
(separated by a barrier of 15 kcal/mol separates each valley) with close free energy
basins (Fig. 6.3). One minimum (A in Fig. 6.3) correspond to the structure found
through Xray diffraction by Wehrman et al. (40). It is centered at θ1, θ2 = 64◦, 105◦.
The second minimum (B) features a root mean square deviation (RMSD) of 6 A˚ with
respect to the previous one. It is centered at θ1, θ2 = 75◦, 110◦. It is characterized by
a large extension of the two TrkA chains. The last two minima (C-D) feature values
of θ1, θ2 = 80◦, 65◦ and 50◦, 60◦, respectively (Fig. 6.3). These conformations involve
a large-scale rearrangment with respect to the X-ray structure (RMSD of 26 and 21
A˚, respectively). As a result, NGF and TrkA are in closer proximity than in the other
minima. These minima feature an asymmetric (C) and symmetric (D) displacement of
the two TrkA chains (Fig. 6.3). The IgG-C1 subdomain is elongated with respect to
A and B. This might corroborate the model by Zaccaro et al. (164), based on which
the IgG-C1 subdomain is a hinge region regulating TrkA conformation and activation
through large-scale conformational changes.
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Figure 6.3: Free energy landscape of NGF/TrkA complex. Free energy basins are
highlighted and shown by representative snapshots. NGF chains are shown in blue and
green, TrkA chains are shown in gold and glycosilation sites are shown by light-blue sticks.
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6.3.2 Validation with experimental data.
In order to validate our result with available experimental data, we calculated the
theoretical CD spectrum (394) for the 4 minima using the parameters from (395) and
compared it with the experimental spectrum (396).
The results point to a global preservation of the secondary structure with respect to
the X-ray structure (40) also in farther minima C and D (Fig. 6.4a, 6.4b).
Figure 6.4: CD spectra. a) Calculated CD spectra for the four minima, and their
average (b). c) Experimental NGF/TrkA CD spectrum (396). TrkA-RED indicates the
experimental spectrum for TrkA alone, NGF the one for NGF alone, CALC is the average
of the former two and MIX is the experimental spectrum for NGF/TrkA complex.
6.4 Discussion and conclusions.
Our calculations point out the existence of four isoenergetic minima of the NGF/TrkA
complex. These minima eincompass as much as the 99.9 % of the total conformational
space. Two of the minima (A, B in Fig. 6.3 turned out to be close to the initial,
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X-ray structure (40). The other two (C, D in Fig. 6.3 feature instead significant
conformational changes showing symmetric and asymmetric stretching of the Ig-C1
and LRR arms.
From one hand, this information might help structure-based drug design of peptide
NGF mimics in conformations A-D, with possible applications in the fight against
Alzheimer’s and other neurodegenerative diseases (397, 398). Indeed, these mimic could
act with either agonist or competitive antagonist on the TrkA receptor by exerting a
neurotrophic effect (150).
From the other hand, our findings may have relevance for reported biological studies:
(i) Several experimental studies pinpointed the crucial role of NGF loop II (residues
40-49) for TrkA binding (163, 399, 400, 401). In the NGF/TrkA crystal structure (40),
loop II does not interact with TrkA. However, the C-term of TrkA (residues 383-423)
is missing in the X-ray structure (40, 163). In structures B, C, D, the orientation of
the TrkA C-term with respect to NGF loop II changes significantly (Fig. 6.5). In
particular, in B and D, one of the TrkA C-terms is located very close to the loop II of
both NGF chains, suggesting that the interaction between TrkA and NGF loop II may
be possible (Fig. 6.5b, 6.5d). This unprecedented finding provides a structural basis
for the experimental observations in references (163, 399, 400, 401).
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Figure 6.5: NGF-TrkA minima A, B, C, D (orange surface). The TrkA C-terms are
displayed in cyan cartoons, the NGF loops II in blue cartoons.
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(ii) In vivo and in vitro data indicate that p75 (a member of the tumor necrosis
factor (TNF) receptor family (378) interacts with TrkA functionally (402, 403, 423),
although likely depending on downstream signaling rather than physical complexes in-
volving the two receptors (40). However, a very short-lived interaction between p75
and TrkA through the formation of a ternary complex might exist (379). At the specu-
lative level, we suggest here that one or more than one minima A-D could play for the
formation of this transient complex. NGF and TrkA have been shown to be involved
in other 45 protein interactions (404). For some of them, the presence of different
conformations A-D might play a role, albeit such role is speculative at present.
In conclusions our study shows that the NGF/TrkA complex adopts a different
structure in water than in the crystal phase. This finding may have relevance for
future ligand design studies and it does shed light on molecular biology studies on this
pharmaceutically relevant system.
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Providing molecular details of protein/protein interactions and integrating them in in-
teraction networks may help understand greatly regulatory pathways, including those
involved in human diseases (25). It also allows the design of protein-protein interaction
inhibitors such as small molecules and peptides, which play an increasingly important
role in pharmacology (405, 406).
Computational methods are an essential tool for structural proteomics studies.
They include several techniques such as homology modeling, classical molecular dy-
namics, protein-protein docking and free energy calculations.
In this thesis, we investigated a variety of pharmacologically relevant protein com-
plex systems. By using an arsenal of computational approaches we have faced challenges
ranging from structural predictions to quantitative investigations of the energetics of
complexes in aqueous solution.
I first focused on complexes involved in the development of optimized immunotoxins.
These represent a novel therapeutic strategy against cancer (53). These immunotox-
ins are recombinantly built by attaching potent toxins (usually of bacterial origin) to
antibody fragments that target cell-surface antigens (49). New generation constructs,
based on human proteins, are able to prevent the formation of neutralizing antibodies
(407).
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In this context, an optimal strategy is based on human Granzyme B, a human ser-
ine protease with apoptotic activity able to kill tumor cell lines (31). Currently, the
therapeutic usage of Granzyme B-based constructs is impaired by a major drawback,
i.e. the in vivo protein inhibition by another serine protease, Serpin B9 (68). I ra-
tionally designed Granzyme B mutants able to show a reduced binding to Serpin B9
while retaining their catalytic activity. This was achieved by a structural prediction of
the Granzyme B-Serpin B9 complex. This prediction was challenging because both the
structure of Serpin B9 and the Granzyme B-Serpin B9 binding mode were not known.
For this reason, we first predicted the Serpin B9 3D structure based on the analogous
structure of another protein of the same family, Serpin B1. The next step was the struc-
tural prediction of the Granzyme B-Serpin B9 complex, based on the known structure
of an analogous complex, the one between Serpin B9 and Trypsin. Finally, we identi-
fied the most important determinants of the interaction between the two proteins (the
so-called hot spots) and observed the effect of their mutation along molecular dynam-
ics simulations. Among the designed Granzyme B mutants, we selected three variants
able to weaken the binding to Serpin B9. In vitro experiments performed by the group
of Prof. Barth (Fraunhofer Institute, RWTH Aachen) validated our predictions. The
three variants, in presence of Serpin B9, retained a catalytic activity comparable to the
one of the isolated wild-type Granzyme B.
Then, we turned out attention to a system for which very limited experimental in-
formation is available. This is the complex between the GSK3β and PARP10 proteins
involved in cancer pathways. PARP10 features mono-ADP-ribosylation activity (34).
GSK3β may provide glutamate residue to perform the reaction (34). Here I carried out
extensive and systematic protein-protein docking studies using this information as input
in the calculations. The structural models of the complexes were tested against in vitro
mutation and ADP-ribosylation assays performed by the group of Prof. Lu¨scher at the
Clinics of the RWTH Aachen University. Ultimately this study, while leaving specific
questions still open, showed the crucial importance of a fully integrated experimental
and computational approach in unveiling the molecular details of protein-protein inter-
actions.
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We finally moved from a qualitative description to a quantitative energetics analysis
of protein-protein interactions. We focused on the neurotrophin NGF, a growth factor
essential for the nervous system function (374), and its receptor TrkA. The dysregu-
lation of NGF-mediated signaling has been related to Alzheimer’s disease (408), being
this signaling required for the long-term survival of nucleus basalis cholinergic neurons
(409). Understanding of the details of NGF/TrkA interaction represents a crucial step
to obtain new insights into the downstream pathways linked to neurodegeneration. This
latter work has been done in collaboration with Dr. Adriana Pietropaolo (U. Catan-
zaro, Italy). In particular, Dr. Pietropaolo carried out the free energy calculations
presented here.
Free energy calculations on the NGF/TrkA X-ray complex (40) allowed to iden-
tify four isoenergetic conformers present in solution. Two of them are significantly
different with respect to the known crystal structure (40). The calculations are in
agreement with all the available experimental data. These include on one hand the
circular dichroism experiments performed on the NGF/TrkA complex (396) and on
the other hand all of the biochemical evidences (163, 399, 400, 401) which point to a
functional role of NGF loop II binding to TrkA, which is not evident from the crystal
structure (40). These results might help design rationally peptide mimics based on the
previously unrecognized NGF/TrkA conformations. These mimics might function as
NGF/TrkA signaling modulators, hence interfering with the derangement associated
with the development of Alzheimer’s disease.
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Appendix A
Design of Human Granzyme B
Variants resistant to Serpin B9.
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A. DESIGN OF HUMAN GRANZYME B VARIANTS RESISTANT TO
SERPIN B9.
Mutation ∆∆G (kcal/mol)
Y17 hSB·hSB9 0.1
K24 hSB·hSB9 0.6
S25 hSB·hSB9 0.1
L26 hSB·hSB9 0.4
K27 hSB·hSB9 1.2
R28 hSB·hSB9 1.5
H44 hSB·hSB9 0.9
F85 hSB·hSB9 0.8
L133 hSB·hSB9 0.6
K135 hSB·hSB9 0.4
H136 hSB·hSB9 0.6
Y160 hSB·hSB9 0.4
Y199 hSB·hSB9 0.4
R201 hSB·hSB9 1.6
Table A.1: Alanine Scanning. Change in free energy calculations of the mutation
to Ala of residues at the hGB·hSB9 interface in the complex, as obtained by using the
Robetta webserver (28, 264). The top three mutations destabilizing the complex are in
bold face. These values are very approximate and should be taken here only for relative
comparisons.
Complex Water molecules Counterions
wt hSB·hSB9 27,615 7 Cl-
K27A hSB·hSB9 28,055 6 Cl-
R28A hSB·hSB9 28,055 6 Cl-
R28E hSB·hSB9 27,644 5 Cl-
R28K hSB·hSB9 27,995 7 Cl-
R28A-R201A hSB·hSB9 27,647 5 Cl-
R201A hSB·hSB9 28,055 6 Cl-
R201E hSB·hSB9 27,644 5 Cl-
R201K hSB·hSB9 27,615 7 Cl-
Table A.2: Details of the simulations. Number of water molecules and counterions
added to the complexes.
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Figure A.1: Template for homology modeling. a) Cartoon of the hGB structure
(67). The catalytic S183 residue, which forms a covalent bond with P1 in S9 (321),
is depicted in red sticks. (b) Cartoon of the rat Trypsin(silver)-M.sexta Serpin B1(green)
complex structure (319) used as template for the structural prediction of the wt hGB·hSB9
complex.
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Figure A.2: Structure of wt hGB·hSB9 The hotspots in hGB (yellow spheres), emerg-
ing here from Baker’s alanine scanning procedure (28, 264) using the Robetta webserver
(Table A.1), are represented by yellow spheres.
Salt bridges Hydrogen bonds Hydrophobic contacts
D189-K353 S147-E191 F41-L355
Q192-P352 F41-I356
Q192-S354 L99-P352
G193-K353 W215-I350
A195-K353 W215-V351
S214-K353 W215-P352
Y39-L357
Table A.3: Trypsin-Serpin B1 interactions. Contacts at the interface between rat
Trypsin and M. sexta Serpin B1, as emerging from the X-ray structure (319).
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Figure A.3: Structures of wt and mutated hGB·hSB9 complexes. a) wt
hGB·hSB9 (thick line) and R28K, R201A, R201K hGB·hSB9; b) wt hGB·hSB9 and the
other mutants (R28A, R28E, R201E, R28A-R201A, K27A hGB·hSB9). The last MD snap-
shots are shown for all systems.
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SERPIN B9.
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Appendix B
NGF binding to p75 and
downstream signaling pathways.
The three-dimensional structure of NGF in a complex with the extracellular domain of
p75 (410) reveals an unexpected 2:1 NGF:p75 stoichiometry, with NGF appearing as
a distorted dimer, which leads to the hypothesis that p75NTR binding to one side of
NGF induces a bending of the entire NGF and disables the binding of a second p75NTR
to the opposite site. This is in contrast with the complex between p75NTR and the
neurotrophin NT3, where NT3 is a perfect homodimer, and the p75NTR receptors bind
symmetrically to form a 2:2 cluster (411).
Historically, p75NTR was the first neurotrophin receptor to be identified as a NGF-
binding transmembrane protein (412, 413). However, due to the lack of readily iden-
tifiable signal transducing modules, it was shown that p75NTR functions as a Trk
co-receptor that increases its NGF binding affinity (414, 415).
As other members of the TNF receptors were demonstrated to modulate apoptotic
responses (416), a potential role for p75NTR as a mediator of cell death was first hy-
pothesized (417).
Indeed, in vitro analyses have shown that p75NTR induces cell death in hippocampal
(418, 419) and sympathetic neurons (420, 421). In vivo, p75NTR plays a prominent
role in apoptosis that occurs in neurons after traumatic injury (422) and has been im-
plicated in developmental apoptosis in the peripheral nervous system (421). On the
other hand, a large number of studies establish NGF-p75NTR interactions as a critical
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PATHWAYS.
biological event that governs life and death decisions in neuronal and non-neuronal
cells (423). When p75NTR and TrkA are expressed in the same cell, however, survival
signaling dominates (424).
In contrast, survival signaling predominantly reflects Trk activation (424). Upon NGF
binding, adjacent TrkA receptors dimerize and undergo trans-autophosphorylation, fol-
lowed by the activation of intracellular survival signaling cascades (128). The main
events are represented by i) the activation of the phosphatidylinositol-3 (PI-3)-kinase/Akt
pathway. These kinases were shown to be both necessary and sufficient for the survival
of NGF-dependent sympathetic neurons (425); ii) the activation of the RAS/mitogen-
activated protein (MAP) kinase cascade, leading to the phosphorylation of the tran-
scription factor CREB and the activation of immediate-early genes (426).
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